Document:

<PAGE>

                                                                     EXHIBT 10.7

                                EMPLOYEE BENEFITS

                                       AND

                        COMPENSATION ALLOCATION AGREEMENT

                                     BETWEEN

                              PHARMACIA CORPORATION

                                       AND

                                MONSANTO COMPANY

                          DATED AS OF SEPTEMBER 1, 2000
<PAGE>

                                TABLE OF CONTENTS

<TABLE>
<CAPTION>
                                                                                                  PAGE
                                                                                                  ----
     <S>            <C>                                                                            <C>
      ARTICLE I.     EMPLOYEE ALLOCATION; SEVERANCE.................................................1
         1.1        Employees.......................................................................1
         1.2        Former Employees................................................................2
         1.3        Severance and Severance Pay.....................................................3
         1.4        Employment Agreements...........................................................3

      ARTICLE II.    U.S. PLANS AND STOCK PLANS.....................................................3
         2.1        Qualified Pension Plans.........................................................3
         2.2        Nonqualified Pension Plans......................................................5
         2.3        SIPs............................................................................5
         2.4        SIP Parity Plan.................................................................7
         2.5        Welfare Plans...................................................................7
         2.6        Individual Supplemental Retirement Agreements...................................9
         2.7        Deferred Payment Plan...........................................................9

      ARTICLE III.   FOREIGN PLANS AND TCN POLICY...................................................9
         3.1        In General......................................................................9
         3.2        Monsanto Company Third Country National Policy..................................9

      ARTICLE IV.    GENERAL PROVISIONS....,.......................................................10
         4.1        Recognition of Employment Service..............................................10
         4.2        Benefit Expenses...............................................................10
         4.3        Audits and Disputes............................................................11
         4.4        Indemnification................................................................12
         4.5        Transferred Employees..........................................................12
         4.6        Administration.................................................................13
         4.7        Workers' Compensation Excluded.................................................14
         4.8        Merger Agreement...............................................................14

      ARTICLE V.     MISCELLANEOUS.................................................................15
         5.1        Guarantee of Subsidiaries' Obligations.........................................15
         5.2        Sharing of Information.........................................................15
         5.3        Termination....................................................................15
         5.4        Rights to Amend or Terminate Plans.............................................15
         5.5        Complete Agreement.............................................................15
         5.6        Governing Law..................................................................15
         5.7        Notices........................................................................16
         5.8        Amendment and Modification.....................................................16
         5.9        Successors and Assigns; No Third-Party Beneficiaries...........................16
         5.10       Counterparts...................................................................16
         5.11       Interpretation.................................................................16

</TABLE>

                                      -i-
<PAGE>

 <TABLE>
      <S>          <C>                                                                            <C>
         5.12       Legal Enforceability...........................................................16
         5.13       References; Construction.......................................................16

      ARTICLE VI.    DEFINITIONS...................................................................16
         6.1        General........................................................................16

      SCHEDULE I.    CERTAIN INDIVIDUAL EMPLOYMENT AGREEMENTS

      SCHEDULE II.   HOST GROUPS

      SCHEDULE III.  COMPUTATION OF TRANSFER VALUE

      SCHEDULE IV.   TREATMENT OF FOREIGN PLANS AND CERTAIN
                     MONSANTO FOREIGN FORMER EMPLOYEES

SCHEDULE V.          INITIAL COMMITTEE MEMBERS
</TABLE>

                                     -ii-
<PAGE>

                       EMPLOYEE BENEFITS AND COMPENSATION
                              ALLOCATION AGREEMENT

                  EMPLOYEE BENEFITS AND COMPENSATION ALLOCATION AGREEMENT, dated
as of September 1, 2000, by and between Pharmacia Corporation, a Delaware
corporation ("Pharmacia"), and Monsanto Company, a newly formed Delaware
corporation ("AgCo").

                              W I T N E S S E T H:

                  WHEREAS, AgCo and Pharmacia are entering into a Separation
Agreement of even date herewith (the "Separation Agreement"), which, among other
things, sets forth the principal corporate transactions required to effect the
Separation and the IPO (as those terms are defined in the Separation Agreement)
and sets forth other agreements that will govern certain other matters prior to
and following the Separation and the IPO; and

                  WHEREAS, pursuant to the Separation Agreement, AgCo and
Pharmacia desire to provide for the allocation of assets and liabilities and
other matters relating to employee benefit plans and compensation arrangements;

                  NOW, THEREFORE, in consideration of the premises and the
mutual covenants herein contained and intending to be legally bound hereby, the
parties hereto agree as follows:

                                  ARTICLE I.

                         EMPLOYEE ALLOCATION; SEVERANCE

     1.1 EMPLOYEES.

     (a) ALLOCATION. Monsanto Employees shall be classified as AgCo Employees or
Pharmacia Employees for purposes of this Agreement as set forth in this Section
1.1(a). Foundation Employees who work primarily outside the U.S. shall be AgCo
Employees if the AgCo Group is the Host Group for the country in which they are
based, and Pharmacia Employees if the Pharmacia Group is the Host Group in such
country. The Foundation Employees providing shared services under the Services
Agreement shall be Pharmacia Employees. Except as set forth above or as agreed
by AgCo and Pharmacia and reflected in their human resources data bank, (i)
individuals who are, immediately before the Separation Date, Monsanto Employees
working exclusively in the Monsanto Business, including those in corporate staff
positions that support exclusively the Monsanto Business, shall be considered
AgCo Employees; (ii) individuals who are, immediately before the Separation
Date, Monsanto Employees working exclusively in the Pharmacia Business,
including those in corporate staff positions that support exclusively the
Pharmacia Business, shall be considered Pharmacia Employees; (iii) Foundation
Employees who work primarily in St. Louis, Missouri shall be AgCo Employees; and
(iv) Foundation Employees who work primarily in Chicago, Illinois, shall be
Pharmacia Employees.
<PAGE>

     (b) TRANSFERS. AgCo and Pharmacia shall take all steps necessary and
appropriate so that, on or immediately after the Separation Date, all AgCo
Employees are employed by a member of the AgCo Group and all Pharmacia Employees
are employed by a member of the Pharmacia Group. Such steps shall include, where
employment does not continue by operation of law or where otherwise necessary or
appropriate under local law, making employment offers and/or transferring
contracts of employment.

     (c) RESIGNATIONS. Except as otherwise agreed by Pharmacia and AgCo,
effective as of the Separation Date, all AgCo Employees who are acting as
directors or officers of any member of the Pharmacia Group shall resign from
such positions, and all Pharmacia Employees who are acting as directors or
officers of any member of the AgCo Group other than AgCo shall resign from such
positions.

     1.2 FORMER EMPLOYEES.

     (a) U.S. FORMER EMPLOYEES. Monsanto U.S. Former Employees who are, as of
the Separation Date, participating in any of the subplans of the Monsanto
Retiree Medical Plan other than the Pharmacia Retained Retiree Medical Subplans,
or who would be so participating if they had been eligible for retiree medical
benefits at the time they ceased to be Employees of the Monsanto Group, shall be
classified as AgCo Former Employees. Monsanto U.S. Former Employees who are, as
of the Separation Date, participating in the Pharmacia Retained Retiree Medical
Subplans, or who would be so participating if they had been eligible for retiree
medical benefits at the time they ceased to be Employees of the Monsanto Group,
shall be classified as Pharmacia Former Employees. Notwithstanding any other
provision of this Agreement, in the event that an AgCo Employee has announced
his or her intention to retire under the Monsanto Pension Plan with a retirement
date that occurs on or before the IPO Closing Date, such individual shall be
transferred to the Pharmacia Group before his or her retirement date and shall
be treated, from and after such retirement, as a Pharmacia Former Employee.

     (b) FOREIGN FORMER EMPLOYEES. Except as specifically provided in Schedule
IV, individuals who are Monsanto Foreign Former Employees immediately before the
Separation Date shall be classified as AgCo Former Employees or Pharmacia Former
Employees based upon a good faith determination by AgCo and Pharmacia of which
of the following categories properly characterizes such individuals' most recent
active employment with any member of the Monsanto Group. If such employment was
primarily in the Monsanto Business, such individual shall be classified as an
AgCo Former Employee. If such employment was primarily in the Pharmacia
Business, such individual shall be classified as a Pharmacia Former Employee. If
such employment was not primarily in one such business (for example, a corporate
staff position), such individual shall be classified as an AgCo Former Employee
if such employment was in a country for which the AgCo Group is the Host Group,
and a Pharmacia Former Employee if it was in a country for which the Pharmacia
Group is the Host Group. Notwithstanding the foregoing, if at any time on or
before December 31, 2000, AgCo and Pharmacia determine that any one or more such
individuals were so classified in error and agree to correct such error, such
individuals shall be re-classified, and AgCo and Pharmacia shall use their
reasonable best efforts to implement the terms of this Agreement as they apply
to such individuals as if such individuals had been correctly classified as of
the Separation Date.

                                      -2-
<PAGE>

     1.3 SEVERANCE AND SEVERANCE PAY.

     (a) NO TERMINATION. AgCo and Pharmacia agree that, except as specifically
provided by law, individuals who become AgCo Employees pursuant to Section 1.1
shall not be deemed to have experienced a termination or severance of employment
from the Pharmacia Group for purposes of any Plan that provides for the payment
of severance, redundancy, salary continuation or similar benefits (a "Severance
Plan").

     (b) SEPARATION PAY PLANS. AgCo shall establish a separation pay plan (the
"AgCo Separation Pay Plan"), effective as of the Separation Date, that is
substantially similar to the Monsanto Separation Plan. Effective as of the
Separation Date, the AgCo Employees shall cease to be covered by the Monsanto
Separation Plan and shall begin to be covered by the AgCo Separation Pay Plan.

     (c) SEVERANCE LIABILITIES. The AgCo Group shall assume and be solely
responsible for all Severance Liabilities of the Monsanto Group arising in
connection with claims made by or on behalf of AgCo Employees and AgCo Former
Employees arising before, on or after the Separation Date. Notwithstanding the
foregoing, Pharmacia shall be solely responsible for all Severance Liabilities
arising in connection with actual or constructive terminations of employment on
or before the second anniversary of the Separation Date to or with respect to
(i) AgCo Employees who are Foundation Employees and whose employment with the
AgCo Group subsequently terminates, and (ii) Employees designated as AgCo
Employees or Pharmacia Employees who exercise their rights, under local law, to
refuse transfer to the employment of a member of the AgCo Group or the Pharmacia
Group, as applicable.

     1.4 EMPLOYMENT AGREEMENTS. Effective as of the Separation Date: (a) the
members of the AgCo Group shall assume or retain and be responsible for all
Liabilities of the Monsanto Group (i) pursuant to Sections 3, 4 and 5 of the
agreements listed on Schedule I and (ii) to or relating to AgCo Employees under
individual employment agreements other than those listed on Schedule I; and (b)
the members of the Pharmacia Group shall assume or retain and be responsible for
(A) all Liabilities of the Monsanto Group to or relating to Pharmacia Employees
under individual employment agreements and (B) all other Liabilities of the
Monsanto Group under the individual employment agreements listed on Schedule I,
in each case, with such modifications as may be agreed to by the AgCo Group and
such AgCo Employees or the Pharmacia Group and such Pharmacia Employees,
respectively.

                                  ARTICLE II.

                           U.S. PLANS AND STOCK PLANS

     2.1 QUALIFIED PENSION PLANS.

     (a) MONSANTO PENSION PLAN. Until the Pension Transfer Date, the members of
the AgCo Group shall be participating employers, and AgCo Participants shall
continue to participate, in the Monsanto Pension Plan.

                                      -3-
<PAGE>

     (b) AGCO PENSION PLAN.

         (i) At such time as Pharmacia may request, AgCo shall establish a
defined benefit pension plan designed to be a qualified plan under Section
401(a) of the Code (the "AgCo Pension Plan") to provide benefits to AgCo
Employees, and to accept the transfer of assets and assumption of Liabilities
provided for in Section 2.1(b)(ii). Initially, the AgCo Pension Plan shall be
identical in all material respects to the Monsanto Pension Plan (including
without limitation the DEKALB frozen benefits structure), subject to such
changes as AgCo may determine to be necessary or appropriate to comply with the
requirements of qualification under Section 401(a) of the Code. AgCo shall seek
a determination letter with respect to the AgCo Pension Plan, and the AgCo
Employees shall not begin to accrue benefits under the AgCo Pension Plan, and
such transfer and assumption shall not take place, until the first business day
of the first month that begins at least 60 days after AgCo receives such
determination letter or such later date as Pharmacia may determine (the date on
which such accruals begin and such transfer and assumption is effective, the
"Pension Transfer Date").

         (ii) Except as specifically set forth in Section 2.1(b)(iii) and
Article IV, subject to the completion of the asset transfer described in the
next sentence, and effective as of the Pension Transfer Date: (A) the Monsanto
Pension Plan shall transfer to the AgCo Pension Plan, and the AgCo Pension Plan
and the members of the AgCo Group shall assume and be responsible for, all
Liabilities of the Monsanto Pension Plan with respect to benefits accrued by
AgCo Participants through the Pension Transfer Date (including without
limitation pursuant to the DEKALB frozen benefits structure); and (B) the
members of the Pharmacia Group shall have no further responsibility for such
Liabilities. As soon as administratively feasible after the Pension Transfer
Date, there shall be transferred from the trust funding the Monsanto Pension
Plan to the trust designated to fund the AgCo Pension Plan (which may have the
same trustee as the former trust and which may be part of a master trust with
the former trust) a portion of each of the assets thereof, having a value, as of
the Pension Transfer Date, equal to the Transfer Value, but in no event less
than the amount required to be transferred under Section 414(l) of the Code. All
determinations required to implement the foregoing transfer of assets shall be
reasonably and equitably made by the Enrolled Actuary in accordance with
Schedule III hereto. The Enrolled Actuary shall make an initial estimate of the
Transfer Value within 30 days after the Pension Transfer Date, and an initial
transfer of assets equal to such estimated Transfer Value shall be made promptly
thereafter. The final calculation of the Transfer Value shall be completed as
soon as practicable, and a true-up transfer will be made promptly following the
expiration of the 30-day period provided for in Section 2.1(c) and, if
applicable, the resolution of any disagreement pursuant to Section 2.1(c), such
transfer to include an interest adjustment from the Pension Transfer Date to the
date of the true-up transfer at the Interest Rate, as defined on Schedule III.

         (iii) Notwithstanding the foregoing, if Pharmacia determines that the
transfer of liabilities and assets in the manner provided for in Section
2.1(b)(ii) would violate any applicable requirements of the Code or ERISA, or
could reasonably be expected to result in the PBGC's taking action to terminate
the Monsanto Pension Plan, then Pharmacia and AgCo shall cooperate to implement
such transfer in a manner that reaches as close as possible to the same results
without any such violation.

                                      -4-
<PAGE>

         (c) IMPLEMENTATION. AgCo and Pharmacia shall cooperate in (i) making
all amendments to the Monsanto Pension Plan and all appropriate filings required
under the Code or ERISA and any applicable securities laws, (ii) implementing
all appropriate communications with participants, (iii) transferring appropriate
records, and (iv) taking all such other actions as may be necessary and
appropriate to implement the provisions of this Section 2.1 in a timely manner.
If AgCo or Pharmacia disagrees with any determination by the Enrolled Actuary
pursuant to this Section 2.1, the disagreeing party shall have the right, within
30 days after receipt of notice of such determination, to engage, at its own
expense, an independent expert to make the determination of such amount. If the
amount determined by such independent experts should differ, such amount shall
be reasonably and equitably determined by another independent expert selected by
agreement between or among the Enrolled Actuary and such independent experts.

         (d) RETENTION OF LIABILITIES. Except as specifically set forth in this
Section 2.1 or in Article IV, the members of the Pharmacia Group shall assume or
retain, as the case may be, and be solely responsible for, all Liabilities of
the Monsanto Group under the Monsanto Pension Plan.

         2.2 NONQUALIFIED PENSION PLANS. From the Separation Date through the
Pension Transfer Date, the members of the AgCo Group shall be participating
employers, and the AgCo Participants shall continue to participate, in the
Monsanto Non-Qualified Pension Plans. Effective as of the Pension Transfer Date,
the AgCo Group shall establish non-qualified pension plans that initially are
substantially similar to the Monsanto Non-Qualified Pension Plans to provide
benefits to AgCo Participants from and after the Pension Transfer Date. From and
after the Pension Transfer Date, except as specifically set forth in Article IV,
the AgCo Group shall assume and be solely responsible for all Liabilities of the
Monsanto Group for or relating to benefits accrued through the Pension Transfer
Date by or with respect to AgCo Participants under the Monsanto Non-Qualified
Pension Plans and the Pharmacia Group shall retain and be solely responsible for
all other Liabilities under the Monsanto Non-Qualified Pension Plans.

         2.3 SIPS.

         (a) MONSANTO SIP. Until the SIP Transfer Date, the members of the AgCo
Group shall be participating employers, and AgCo Participants shall continue to
participate, in the Monsanto SIP.

         (b) AGCO SIP. Effective as of, or as soon as administratively feasible
after, January 1, 2001, AgCo shall establish a defined contribution plan
designed to be a qualified plan under Section 401(a) of the Code (the "AgCo
SIP") and a related trust (the "AgCo SIP Trust") (which may have the same
trustee as the Monsanto SIP Trust and which may be part of a master trust with
the Monsanto SIP Trust) to assume Liabilities of and receive the transfers of
assets from the Monsanto SIP and the Monsanto SIP Trust as provided for in this
Section 2.3 (the date on which such transfers are effective, the "SIP Transfer
Date"). Initially, the AgCo SIP shall be identical in all material respects to
the Monsanto SIP.

                                      -5-
<PAGE>

         (c) TRANSFER OF ACCOUNTS. AgCo and Pharmacia shall cause the balances
of all accounts established pursuant to and/or governed by the Monsanto SIP of
the participants in the Monsanto SIP who are, as of the SIP Transfer Date, AgCo
Participants to be transferred to the AgCo SIP and the AgCo SIP Trust. The
transfer of such accounts shall be made (i) in kind, to the extent the assets
thereof consist of Employer Securities, and (ii) otherwise in cash, securities,
other property or a combination thereof, as agreed by Pharmacia and AgCo, but
shall be effected, where practicable, in kind, so as to preserve each such
participant's investment elections as in effect on the date of such transfer.
Any Employer Securities transferred to the AgCo SIP in accordance with the
foregoing that constituted ESOP Financed Shares immediately before the SIP
Transfer Date shall be considered ESOP Financed Shares in the AgCo SIP.

         (d) ESOP RESTRUCTURING. Effective as of the SIP Transfer Date, in a
manner and on such terms and conditions as are consistent with applicable
fiduciary requirements, one or more of the Existing Monsanto ESOP Securities
shall be restructured into two separate obligations, with one of such
obligations (each, an "AgCo ESOP Security") being assumable or issued by the
AgCo SIP and the remainder thereof (each, a "New Monsanto ESOP Security") being
issued by the Monsanto SIP. The aggregate principal amount of the AgCo ESOP
Securities shall be as nearly as possible equal to (i) the aggregate principal
amount of the Existing Monsanto ESOP Securities immediately before such
restructuring times (ii) the ESOP Fraction, and the aggregate principal amount
of the New Monsanto ESOP Securities and any Existing Monsanto ESOP Securities
that are not so restructured shall equal the excess of (I) the aggregate
principal amount of the Existing Monsanto ESOP Securities immediately before
such restructuring over (II) the aggregate principal amount of the AgCo ESOP
Securities. The AgCo ESOP Securities may include one or more loans from AgCo
and/or one or more loans from Pharmacia that are assignable to AgCo
(collectively, the "AgCo ESOP Loan"). Pharmacia and AgCo shall use their
reasonable best efforts, in a manner and on such terms and conditions as are
consistent with applicable fiduciary requirements, to cause the terms of the
AgCo ESOP Securities and New Monsanto ESOP Securities to be as favorable to AgCo
and the AgCo SIP Trust and to Pharmacia and the Monsanto SIP Trust,
respectively, as the terms of the Existing Monsanto ESOP Securities, to the
extent possible. Effective as of the SIP Transfer Date: (i) the AgCo SIP Trust
shall assume all obligations of the Monsanto SIP Trust (if any) under the AgCo
ESOP Securities; (ii) Pharmacia shall be released from any guarantees it has
given with respect to the AgCo ESOP Securities, and AgCo shall provide such
guarantees; and (iii) Pharmacia shall assign all of its rights (if any) under
the AgCo ESOP Loan to AgCo. Subject to and upon the completion of the
restructuring, assumption, release and assignment described in the preceding
sentences of this Section 2.3(d), the trustee of the Monsanto SIP Trust shall
transfer to the AgCo SIP Trust a PRO RATA portion of each of the assets held in
each of the ESOP Interim Account, the Monsanto ESOP Payment Account and the ESOP
Suspense Account established pursuant to Section 19 of the Monsanto SIP,
representing a percentage of such assets that equals the ESOP Fraction, and such
accounts shall be accepted by the AgCo SIP and the AgCo SIP Trust.

(e) IMPLEMENTATION. AgCo and Pharmacia shall cooperate in making all appropriate
plan amendments, making all filings required under the Code or ERISA and any
applicable securities laws, implementing all appropriate communications with
participants, maintaining and transferring appropriate records, and taking all
such other actions as may be necessary and appropriate to implement the
provisions of this Section 2.3 and to cause the transfers of assets and
Liabilities pursuant to Sections 2.3(c) and 2.3(d) to take place effective as

                                      -6-
<PAGE>

of or as soon as administratively feasible after January 1, 2001; PROVIDED,
HOWEVER, that such transfers shall not take place before the receipt of an
opinion of counsel satisfactory to Pharmacia and AgCo to the effect that the
AgCo SIP is in form qualified under Section 401(a) of the Code, the employee
stock ownership plan portion of the AgCo SIP is in form qualified under Section
4975 of the Code and the AgCo SIP Trust is in form exempt under Section 501(a)
of the Code.

         (f) ASSUMPTION OF LIABILITIES. Except as specifically set forth in this
Section 2.3 or in Article IV, subject to the completion of the transfers
provided for in Sections 2.3(c) and 2.3(d), and effective as of the SIP Transfer
Date, the members of the AgCo Group and the AgCo SIP shall assume or retain, as
the case may be, and shall be solely responsible for all Liabilities of the
Monsanto Group to or with respect to AgCo Participants under the Monsanto SIP,
and the members of the Pharmacia Group shall assume or retain, as the case may
be, and be solely responsible for, all other Liabilities of the Monsanto Group
under the Monsanto SIP. The members of the AgCo Group and the AgCo SIP shall be
solely responsible for all Liabilities arising out of or relating to the AgCo
SIP.

         2.4 SIP PARITY PLAN. From the Separation Date through the SIP Transfer
Date, the members of the AgCo Group shall be participating employers, and AgCo
Participants shall continue to participate, in the Monsanto SIP Parity Plan.
Effective as of the SIP Transfer Date, the AgCo Group shall establish a
non-qualified defined contribution plan that initially is identical in all
material respects to the Monsanto SIP Parity Plan to provide benefits to AgCo
Participants from and after the SIP Transfer Date. From and after the SIP
Transfer Date, except as specifically set forth in Article IV, the members of
the AgCo Group shall assume and be solely responsible for all Liabilities of the
Monsanto Group for or relating to benefits accrued through the SIP Transfer Date
by or with respect to AgCo Participants under the Monsanto SIP Parity Plan and
the Pharmacia Group shall retain and be solely responsible for all other
Liabilities under the Monsanto SIP Parity Plan.

         2.5 WELFARE PLANS.

         (a) IN GENERAL. Except as specifically set forth in this Section 2.5,
AgCo and Pharmacia shall take, and shall cause the members of their respective
Groups to take, all actions necessary or appropriate so that, (i) effective as
of, or as soon as practicable after, the Separation Date, AgCo shall have
assumed sponsorship of the Monsanto U.S. Welfare Plans, (ii) the members of the
Pharmacia Group shall be participating employers therein, and (iii) Pharmacia
Participants shall continue to participate therein, through December 31, 2001 or
such earlier date as AgCo and Pharmacia may agree. AgCo and Pharmacia shall use
reasonable best efforts to assign to AgCo all insurance contracts that insure
benefits under any of the Monsanto U.S. Welfare Plans. Effective as of
January 1, 2002 or such earlier date as AgCo and Pharmacia may agree, the
Pharmacia Group shall establish its own U.S. Welfare Plans (the "New Pharmacia
U.S. Welfare Plans") to cover Pharmacia Participants, and the members of the
Pharmacia Group shall cease to be participating employers, and Pharmacia
Participants shall cease to participate, in the Monsanto U.S. Welfare Plans.
Each New Pharmacia U.S. Welfare Plan shall, to the extent permitted by
applicable law, provide benefits to Pharmacia Participants without interruption
or change solely as a result of the transition from the corresponding Monsanto
U.S. Welfare Plan, and, without limiting the generality of the foregoing, shall:
(i) to the extent applicable, recognize

                                      -7-
<PAGE>

all amounts applied to deductibles, out-of-pocket maximums and lifetime maximum
benefits with respect to Pharmacia Participants under the corresponding Monsanto
U.S. Welfare Plan for the plan year (if any) during which they begin to
participate in the New Pharmacia U.S. Welfare Plan and for prior periods (if
applicable); (ii) to the extent applicable, not impose any limitations on
coverage of pre-existing conditions of Pharmacia Participants, except to the
extent such limitations applied to such Pharmacia Participants under the
corresponding Monsanto U.S. Welfare Plan immediately before they begin to
participate in such New Pharmacia U.S. Welfare Plan; and (iii) not impose any
other conditions (such as proof of good health, evidence of insurability or a
requirement of a physical examination) upon the participation by Pharmacia
Participants who were participating in the corresponding Monsanto U.S. Welfare
Plan immediately before such New Pharmacia U.S. Welfare Plan became effective.

         (b) RETIREE WELFARE PLANS. AgCo shall establish, effective as of the
Separation Date, one or more retiree medical and life insurance benefit plans
(collectively, the "AgCo 2000 Retiree Welfare Plan"), to provide benefits to
eligible AgCo Participants. The AgCo 2000 Retiree Welfare Plan initially shall
include subplans that provide benefits that are identical in all material
respects to the benefits provided immediately before the Separation Date under
each of the subplans of the Monsanto Retiree Welfare Plans other than the
Pharmacia Retained Retiree Welfare Subplans. From and after the Separation Date,
except as set forth in Article IV: (i) the members of the AgCo Group shall be
solely responsible for all Liabilities under all subplans of the AgCo 2000
Retiree Welfare Plans; and (ii) the members of the Pharmacia Group shall assume
or retain, as the case may be, and be solely responsible for, all Liabilities of
the Monsanto Group under the Pharmacia Retained Retiree Welfare Subplans.
Effective as of the Separation Date, Pharmacia shall cause all subplans of the
Monsanto Retiree Welfare Plans other than the Pharmacia Retained Retiree Welfare
Subplans to be terminated.

         (c) PREMIUM HOLIDAY. It is anticipated that because of the receipt of
proceeds attributable to the demutualization of the Metropolitan Life Insurance
Company allocable to employee-paid premiums, participants in certain of the
Monsanto U.S. Welfare Plans will enjoy a premium holiday for some portion of the
period during which both AgCo Participants and Pharmacia Participants will be
participating in those plans. AgCo and Pharmacia agree that any such premium
holiday will apply to AgCo Participants and Pharmacia Participants on the same
basis, without discrimination on the basis of their status as AgCo Participants
or Pharmacia Participants, respectively.

         (d) SPLIT DOLLAR POLICIES. AgCo and Pharmacia shall take all actions
necessary or appropriate to assign to AgCo, effective as of the Separation Date,
all of the rights and interests of the Monsanto Group in the split dollar life
insurance policies insuring the lives of AgCo Participants pursuant to the Split
Dollar Life Insurance Program (such policies, the "Assigned Split Dollar
Policies"). Such actions shall include AgCo's acceptance of any collateral
assignments, policy endorsements or such other documentation executed by or on
behalf of such AgCo Participants or any trustee of any trust to which any AgCo
Participant's policy rights or incidents of ownership under the Assigned Split
Dollar Policies have been assigned, and AgCo's entering into such agreements as
may be necessary to fulfill any obligations of Pharmacia to any insurance
company or insurance agent or broker under the Assigned Split Dollar Policies.
From and after the date of the assignment of any Assigned Split Dollar Policy to
AgCo, AgCo shall assume and be solely responsible for all Liabilities, and shall

                                      -8-
<PAGE>

be entitled to all benefits, of the Monsanto Group to the applicable AgCo
Participant under the Split Dollar Life Insurance Program, including under such
policies and any related agreements entered into by such AgCo Participant or any
such trustee.

         (e) CERTAIN RESERVES. AgCo and Pharmacia shall take all action
necessary or appropriate to cause Metropolitan Life Insurance Company to
partition between AgCo and Pharmacia, effective as of the Separation Date, the
rate stabilization reserves maintained in connection with the Monsanto Company
Salaried and Non-Union Hourly Employees' Term Life Insurance Plan, the Monsanto
Company Salaried and Non-Union Employees' Dependent Term Life Insurance Plan,
the Monsanto Company Hourly-Paid Employees' Group Life Insurance and Sickness
Plan-Union, and the Monsanto Company Optional Life Insurance Plan-Union, based
upon the relative dollar amount of premiums to be paid by each of them with
respect to the coverage to which such reserves relate, determined immediately
after the Separation Date.

         2.6 INDIVIDUAL SUPPLEMENTAL RETIREMENT AGREEMENTS. Except as
specifically set forth in Article IV, and effective as of the Separation Date,
the members of the AgCo Group shall assume and be solely responsible for all
Liabilities of the Monsanto Group to or relating to AgCo Participants under all
Monsanto Individual Supplemental Retirement Agreements. Except as specifically
set forth in Article IV, and effective as of the Separation Date, Pharmacia
shall assume or retain, and be solely responsible for, all Liabilities of the
Monsanto Group to or relating to Pharmacia Participants under all Monsanto
Individual Supplemental Retirement Agreements.

         2.7 DEFERRED PAYMENT PLAN. Effective as of the Separation Date, the
AgCo Group shall establish a non-qualified deferred compensation plan that
initially is substantially similar to the Monsanto Deferred Payment Plan to
provide benefits to AgCo Participants from and after the Separation Date. From
and after the Separation Date, except as specifically set forth in Article IV,
the AgCo Group shall assume and be solely responsible for all Liabilities of the
Monsanto Group for or relating to benefits accrued through the Separation Date
by or with respect to AgCo Participants under the Monsanto Deferred Payment Plan
and the Pharmacia Group shall retain and be solely responsible for all other
Liabilities under the Monsanto Deferred Payment Plan.

                                  ARTICLE III.

                          FOREIGN PLANS AND TCN POLICY

         3.1 IN GENERAL. The manner in which Foreign Plans shall be treated is
set forth on Schedule IV.

         3.2 MONSANTO COMPANY THIRD COUNTRY NATIONAL POLICY. From and after the
Separation Date, except as specifically set forth in Article IV, the members of
the AgCo Group shall assume or retain, as applicable, and be solely responsible
for all Liabilities of the Monsanto Group to or relating to benefits accrued
through the Separation Date by or with respect to AgCo Participants under the
TCN Policy, and the members of the Pharmacia Group shall assume or retain, as
applicable, and be solely responsible for all other Liabilities under the TCN
Policy.

                                      -9-
<PAGE>

                                  ARTICLE IV.

                               GENERAL PROVISIONS

         4.1 RECOGNITION OF EMPLOYMENT SERVICE. To the extent permitted by
applicable law, and except as would result in duplication of benefits: (a) all
AgCo Plans shall recognize, as service with the AgCo Group, service by AgCo
Employees with any member of the Monsanto Group before the Separation Date and,
in the case of any Transferred Employee, service with any member of the
Pharmacia Group before the Transfer; (b) all Pharmacia Plans shall recognize, as
service with the Pharmacia Group, service by any Transferred Employee with any
member of the AgCo Group before the Transfer; (c) all AgCo Plans shall
recognize, as compensation from the AgCo Group, all compensation from any member
of the Monsanto Group before the Separation Date, and, in the case of any
Transferred Employee, compensation from any member of the Pharmacia Group before
the Transfer, for purposes of determining pay and benefits under any Severance
Plan; and (d) all Pharmacia Plans shall recognize, as compensation from the
Pharmacia Group, all compensation of any Transferred Employee from any member of
the AgCo Group before the Transfer, for purposes of determining pay and benefits
under any Severance Plan.

         4.2 BENEFIT EXPENSES.

         (a) IN GENERAL. During all periods when AgCo Participants are
participating in U.S. Plans sponsored by the Pharmacia Group or Pharmacia
Participants are participating in U.S. Plans sponsored by the AgCo Group, AgCo
or Pharmacia, as applicable, shall bear the expenses of such participation, in
accordance with this Section 4.2. In addition, through December 31, 2000,
Pharmacia shall provide joint payment services with respect to U.S. Welfare
Plans and AgCo shall reimburse Pharmacia for the expenses of benefits under U.S.
Welfare Plans provided to AgCo Participants, as set forth in Section 4.2(b).
Finally, if the AgCo Group or the Pharmacia Group is obligated to pay any third
party administrative expenses or similar charges with respect to any U.S. Plans
in which Pharmacia Participants or AgCo Participants, as applicable, are
participating, then Pharmacia shall reimburse AgCo, or AgCo shall reimburse
Pharmacia, as applicable, for its share thereof, as follows: (i) the Group
paying such expenses and charges shall seek to have the third party provide
separate statements of such expenses and charges attributable to AgCo
Participants, on the one hand, and Pharmacia Participants, on the other hand,
and if such separate statements are provided, each Group shall bear the expenses
and charges shown on its separate statement; and (ii) if such separate
statements are not provided, the AgCo Group and the Pharmacia Group shall share
such expenses and charges in proportion to the relative numbers of participants
in the relevant U.S. Plan, determined as of the beginning of the period to which
the expenses and charges relate, who are AgCo Participants and Pharmacia
Participants.

         (b) U.S. WELFARE PLANS. During the period ending December 31, 2001,
Pharmacia shall make all payments to third parties required to be made pursuant
to all Monsanto U.S. Welfare Plans (including the AgCo 2000 Retiree Welfare
Plans), and AgCo shall reimburse Pharmacia for the expense of providing benefits
with respect to claims incurred by AgCo Participants on or before December 31,
2000, based upon the payroll overhead loader rate that has previously been
established for the year 2000. As soon as practicable after December 31,

                                      -10-
<PAGE>

2000, the administrator of each such Plan shall determine, in a manner
consistent with the current practice of the Monsanto Group, the actual costs of
such participation by AgCo Participants, and there shall be a true-up payment,
as and to the extent necessary to reflect the differences between such actual
costs and the periodic charges already reimbursed. AgCo shall pay directly all
expenses of the AgCo 2000 Retiree Welfare Plan for claims incurred on or after
January 1, 2001. In addition, AgCo and Pharmacia shall cooperate to ensure that
each third-party provider to any U.S. Welfare Plan provides separate invoices
for AgCo Participants and Pharmacia Participants for all claims incurred on or
after January 1, 2001, and each of them shall pay such invoices directly.

         (c) MONSANTO SIP. AgCo shall pay to Pharmacia an amount equal to the
cost basis of the Monsanto SIP Trust for all shares of Pharmacia common stock
that are allocated to the accounts of AgCo Participants in the Monsanto SIP
during the period from the Separation Date through the day before the SIP
Transfer Date, as and when such allocations are made pursuant to the Monsanto
SIP.

         (d) MONSANTO PENSION PLAN. If Pharmacia becomes obligated to make any
contribution to the Monsanto Pension Plan with respect to any plan year or
portion of a plan year that ends before the Pension Transfer Date, AgCo shall
pay to Pharmacia a percentage of such contribution, equal to the percentage of
the normal costs, as determined pursuant to Section 412 of the Code, for such
plan year or portion thereof that is attributable to AgCo Participants.

         (e) FUNDED FOREIGN PENSION PLANS. If any member of the AgCo Group or
the Pharmacia Group becomes obligated to make any contribution to any Foreign
Plan that is a funded pension plan at a time when both AgCo Participants and
Pharmacia Participants are actively participating therein, such contribution
shall be borne by AgCo and Pharmacia as set forth in Schedule IV.

         (f) NONQUALIFIED AND UNFUNDED PENSION PLANS. AgCo shall pay directly,
or reimburse Pharmacia for the amount of all benefit payments made after the
Separation Date to AgCo Participants pursuant to the Monsanto Non-Qualified
Pension Plans, the SIP Parity Plan and all Foreign Plans that are "pension
plans" within the meaning of Section 3(3) of ERISA to the extent benefits under
such Foreign Plans are not provided from any trust fund, insurance policy or
other funding vehicle.

         (g) FOREIGN WELFARE PLANS. AgCo and Pharmacia shall cooperate to
develop and implement appropriate methodologies to accomplish a similar
cost-sharing for Foreign Plans that are Welfare Plans which methodologies shall,
where possible and consistent with the foregoing, be consistent with the current
practice of the Monsanto Group with respect to such Foreign Plans.

         4.3 AUDITS AND DISPUTES

         (a) ALLOCATION OF LIABILITIES. (i) If any audit, examination or similar
proceeding with respect to any Old Monsanto Plan, AgCo Plan or Pharmacia Plan by
the U.S. Internal Revenue Service, the U.S. Department of Labor or any other
governmental authority, or any litigation arising out of such an audit,
examination or similar proceeding, that pertains (in

                                      -11-
<PAGE>

whole or in part) to a period before the Separation Date (with respect to an Old
Monsanto Plan) or to a period during which both AgCo Participants and Pharmacia
Participants are participating in such AgCo Plan or Pharmacia Plan, as
applicable, results in the imposition of any Liability, then the portion of such
Liability that pertains to a period before the Separation Date or during such
joint participation, as applicable (an "Audit Liability"), shall be allocated
between AgCo and Pharmacia as set forth in this Section 4.3, PROVIDED that the
term "Audit Liability" shall not include any portion of such a Liability that
results from the loss of any compensation deduction or any related interest or
penalties (which shall be governed by the Tax Sharing Agreement); and PROVIDED,
FURTHER, that AgCo and Pharmacia shall each bear half of any legal fees and
expenses reasonably incurred by either of them in connection with any such
proceeding or litigation.

         (ii) To the extent that an Audit Liability takes the form of a payment
to any AgCo Participant or Pharmacia Participant of a benefit under a Plan, a
payment in lieu of such a benefit, a contribution to a trust or other funding
vehicle relating to a Plan, or interest on such a payment or contribution, such
Audit Liability shall be allocated between AgCo and Pharmacia in accordance with
the extent to which it is attributable to AgCo Participants or Pharmacia
Participants, respectively.

         (iii) To the extent that an Audit Liability relates to any event or
circumstance involving the employee stock ownership plan portion of the Monsanto
SIP (other than an Audit Liability addressed in Section 4.3(a)(ii)) that
occurred or arose on or before the SIP Transfer Date, a portion of such Audit
Liability equal to the ESOP Fraction shall be allocated to AgCo, and the
remainder thereof shall be allocated to Pharmacia.

         (iv) Any Audit Liability not addressed in Section 4.3(a)(ii) or
4.3(a)(iii) above that takes the form of a penalty, fine or other Liability
imposed as a result of the manner in which a Plan was administered (including as
a result of the failure to make a required filing or participant communication)
shall be allocated between AgCo and Pharmacia in proportion to the relative
numbers of participants in the relevant Plan, determined immediately before the
Separation, who are classified as AgCo Participants and Pharmacia Participants
as of the Separation Date.

         (b) OTHER. If an Audit Liability arises, the allocation of which is not
addressed in Section 4.3(a), or if there arises any other dispute concerning the
allocation of Audit Liabilities, such allocation or dispute shall be subject to
Article VI of the Separation Agreement. Any dispute arising under Section 2.1(c)
or any other dispute, controversy or claim arising out of or relating to this
Agreement shall also be governed by Article VI of the Separation Agreement.

         4.4 INDEMNIFICATION. All Liabilities retained or assumed by or
allocated to the AgCo Group pursuant to this Agreement shall be deemed to be
Monsanto Liabilities pursuant to the Separation Agreement, and all Liabilities
retained or assumed by or allocated to Pharmacia or any other members of the
Pharmacia Group pursuant to this Agreement shall be deemed to be Pharmacia
Liabilities pursuant to the Separation Agreement, and, in each case, shall be
subject to the indemnification provisions set forth in Sections 3.03 and 3.04 of
the Separation Agreement.

         4.5 TRANSFERRED EMPLOYEES. As a result of uncertainties regarding the
respective business needs of the AgCo Group and the Pharmacia Group, certain
individuals who

                                      -12-
<PAGE>

become AgCo Employees or Pharmacia Employees at the Separation
Date may subsequently Transfer to the Pharmacia Group or the AgCo Group,
respectively. AgCo and Pharmacia shall use reasonable best efforts to provide
such Transferred Employees with a smooth transition with respect to employee
benefits, including, where appropriate, by transfer of Plan assets and
Liabilities with respect to the benefits of Transferred Employees under Plans in
a manner similar to that provided under Articles II and III.

         4.6 ADMINISTRATION.

         (a) COMMITTEE STRUCTURE. For so long as AgCo and Pharmacia are treated
as a single employer pursuant to Section 414(b) or (c) of the Code, the
committee structure set forth in this Section 4.6 shall govern with respect to
all AgCo Employee Benefit Plans and Pharmacia Employee Benefit Plans.

         (b) OVERSIGHT COMMITTEE. A committee called the Global Employee
Benefits Oversight Committee (the "Oversight Committee"), consisting initially
of the persons holding the offices set forth in Schedule V, shall exercise all
settlor functions with respect to all AgCo Employee Benefit Plans and Pharmacia
Employee Benefit Plans that either are subject to ERISA or are Foreign Plans, in
each case, to the extent any one exercise of such a function is expected to
involve contributions and/or expenses in excess of $100,000 per year. The Chief
Executive Officer of AgCo shall have the power to remove, replace and appoint
the members of the Oversight Committee who represent AgCo, and the Chief
Executive Officer of Pharmacia shall serve as the chairperson of the Oversight
Committee and shall have the power to remove, replace and appoint the members of
the Oversight Committee who represent Pharmacia; PROVIDED, that such committee
shall at all times include voting members representing both AgCo and Pharmacia,
with the latter not to exceed the former by more than two members.

         (c) INVESTMENT COMMITTEE. A committee called the Global Benefits
Investment Committee (the "Investment Committee") shall serve as the named
fiduciary responsible for investment of assets of all funded AgCo Employee
Benefit Plans and Pharmacia Employee Benefit Plans that are subject to ERISA,
and shall have responsibility for overseeing the investment of plan assets of
all AgCo Employee Benefit Plans and Pharmacia Employee Benefit Plans that are
funded Foreign Plans. The Oversight Committee shall have the power to remove,
replace and appoint members of the Investment Committee, PROVIDED that such
committee shall at all times include voting members representing both AgCo and
Pharmacia, with the latter not to exceed the former by more than two members.

         (d) AGCO COMMITTEES. A committee called the "Monsanto Internal People
Committee," consisting initially of the individuals identified on Schedule V,
shall (i) exercise with respect to all AgCo Plans all settlor and employer
functions that are not made the responsibility of the Oversight Committee
pursuant to Section 4.6(b) and (ii) shall make recommendations to the Oversight
Committee as to how the Oversight Committee shall exercise its responsibilities
with respect to all AgCo Plans. A Committee called the "Monsanto Employee
Benefits Plan Committee," consisting initially of the individuals identified on
Schedule V, shall be the named fiduciary with responsibility for administering
all AgCo Plans, except as provided in Section 4.6(f). The Board of Directors of
AgCo or its delegee shall have the power to remove,

                                      -13-
<PAGE>

replace and appoint members of the Monsanto Internal People Committee and the
Monsanto Employee Benefits Plan Committee.

         (e) PHARMACIA ADMINISTRATIVE COMMITTEE - U.S. PLANS. A committee called
the "Pharmacia Administrative Committee - U.S. Plans" shall (i) be the named
fiduciary with responsibility for administering all Pharmacia Employee Benefit
Plans that are subject to ERISA, except as provided in Section 4.6(f), and (ii)
exercise with respect to all Pharmacia Employee Benefit Plans all settlor and
employer functions that are not made the responsibility of the Oversight
Committee pursuant to Section 4.6(b). The Oversight Committee shall have the
power to remove, replace and appoint members of the Pharmacia Administrative
Committee - U.S. Plans.

         (f) JOINT ADMINISTRATIVE COMMITTEE. A committee called the "Joint
Administrative Committee," consisting initially of the same individuals who
constitute the Monsanto Employee Benefit Plans Committee, shall be the named
fiduciary with responsibility for such administrative functions as may be
delegated to it by the Monsanto Employee Benefits Plan Committee or the
Pharmacia Administrative Committee - U.S. Plans, as applicable, with respect to
AgCo Plans and Pharmacia Plans in which both AgCo Participants and Pharmacia
Participants are participating. The chairperson of the Monsanto Employee
Benefits Plan Committee shall have the power to remove, replace and appoint the
members of the Joint Administrative Committee who represent AgCo, and the
chairperson of the Pharmacia Administrative Committee - U.S. Plans shall have
the power to remove, replace and appoint the members of the Joint Administrative
Committee who represent Pharmacia; PROVIDED, that such committee shall at all
times include an equal number of voting members representing AgCo and Pharmacia.

         (g) DELEGATIONS; NON-VOTING MEMBERS. The committees provided for above
and the Chief Executive Officers of AgCo and Pharmacia shall have the power to
delegate the powers given to them pursuant to this Section 4.6, as they deem
appropriate. In addition, each of AgCo and Pharmacia shall be permitted to
appoint, from time to time, up to two non-voting members to each of the above
committees (or more with the approval of the chairperson of the affected
committee).

         4.7 WORKERS' COMPENSATION EXCLUDED. Notwithstanding any other provision
of this Agreement, this Agreement shall have no application to, and shall not
govern the allocation of, any Liabilities for or relating to workers'
compensation, which are governed by the Separation Agreement.

         4.8 MERGER AGREEMENT. AgCo and Pharmacia agree that, notwithstanding
any provision of this Agreement, they shall comply with, and shall cause the
other members of their respective Groups to comply with, the provisions of
Sections 5.6(a) and 5.6(b) of the Merger Agreement.

                                      -14-
<PAGE>

                                   ARTICLE V.

                                  MISCELLANEOUS

         5.1 GUARANTEE OF SUBSIDIARIES' OBLIGATIONS. AgCo and Pharmacia shall
cause to be performed, and each hereby guarantees the performance and payment
of, all actions, agreements, obligations and Liabilities set forth herein to be
performed or paid by their respective Subsidiaries.

         5.2 SHARING OF INFORMATION. Each of AgCo and Pharmacia shall, and shall
cause each of the other members of their respective Groups to, provide to the
other all such information in its possession as the other may reasonably request
to enable it to administer its employee benefit plans and programs, and to
determine the scope of, and fulfill, its obligations under this Agreement. Such
information shall, to the extent reasonably practicable, be provided in the
format and at the times and places requested, but in no event shall the party
providing such information be obligated to incur any direct expense not
reimbursed by the party making such request, nor to make such information
available outside its normal business hours and premises. The right of AgCo and
Pharmacia to receive information hereunder shall, without limiting the
generality of the foregoing, extend to any and all reports, and the data
underlying such reports, prepared by the Enrolled Actuary in making any
determination under this Agreement. Any such information that is covered by
attorney-client privilege or any similar privilege, protection or right of
confidentiality shall be handled in such a manner as to preserve such privilege
or right.

         5.3 TERMINATION. This Agreement shall be terminated in the event that
the Separation Agreement is terminated and the Separation abandoned prior to the
Separation Date. In the event of such termination, no party hereto shall have
any Liability or obligation of any kind to any Person by reason of this
Agreement.

         5.4 RIGHTS TO AMEND OR TERMINATE PLANS. No provision of this Agreement
shall be construed (a) to limit the right of any member of the AgCo Group to
amend or terminate any AgCo Plan, or the right of any member of the Pharmacia
Group to amend or terminate any Pharmacia Plan, or (b) to create any right or
entitlement whatsoever in any Employee, former Employee or Beneficiary,
including a right to continued employment or to any benefit under a Plan or any
other compensation; PROVIDED, that any amendment to or termination of a Plan
that would materially affect the benefits of AgCo Participants or Pharmacia
Participants or result in a material increase in the benefit expenses borne by
the AgCo Group or the Pharmacia Group may be made only with the approval of AgCo
or Pharmacia, as applicable.

         5.5 COMPLETE AGREEMENT. This Agreement and the agreements and other
documents referred to herein shall constitute the entire agreement between the
parties hereto with respect to the subject matter hereof, and shall supersede
all previous negotiations, commitments and writings with respect to such subject
matter.

         5.6 GOVERNING LAW. Subject to applicable U.S. federal law, this
Agreement shall be governed by and construed in accordance with the laws of the
State of Delaware (other than the laws regarding choice of laws and conflicts of
laws) as to all matters, including matters of validity, construction, effect,
performance and remedies.

                                      -15-
<PAGE>

         5.7 NOTICES. All notices, requests, claims, demands and other
communications hereunder shall be given in accordance with the provisions of
Section 10.05 of the Separation Agreement.

         5.8 AMENDMENT AND MODIFICATION. This Agreement may be amended, modified
or supplemented only by a written agreement signed by both AgCo and Pharmacia.

         5.9 SUCCESSORS AND ASSIGNS; NO THIRD-PARTY BENEFICIARIES. This
Agreement and all of the provisions hereof shall be binding upon and inure to
the benefit of the parties hereto and their successors and permitted assigns,
but neither this Agreement nor any of the rights, interests and obligations
hereunder shall be assigned by any party hereto without the prior written
consent of the other party (which consent shall not be unreasonably withheld or
delayed). This Agreement is solely for the benefit of the parties hereto and
their respective Subsidiaries and Affiliates and is not intended to confer upon
any other Persons any rights or remedies hereunder.

         5.10 COUNTERPARTS. This Agreement may be executed in two or more
counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument.

         5.11 INTERPRETATION. The Article and Section headings contained in this
Agreement are solely for the purpose of reference, are not part of the agreement
of the parties hereto and shall not in any way affect the meaning or
interpretation of this Agreement.

         5.12 LEGAL ENFORCEABILITY. Any provision of this Agreement that is
prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction,
be ineffective to the extent of such prohibition or unenforceability without
invalidating the remaining provisions hereof. Any such prohibition or
unenforceability in any jurisdiction shall not invalidate or render
unenforceable such provision in any other jurisdiction. Each of AgCo and
Pharmacia acknowledges that money damages would be an inadequate remedy for any
breach of the provisions of this Agreement and agrees that their respective
obligations hereunder shall be specifically enforceable.

         5.13 REFERENCES; CONSTRUCTION. References to any "Article," "Schedule"
or "Section," without more, are to Articles, Schedules and Sections to or of
this Agreement. Unless otherwise expressly stated, clauses beginning with the
term "including" set forth examples only and in no way limit the generality of
the matters thus exemplified.

                                  ARTICLE VI.

                                   DEFINITIONS

6.1 GENERAL. Any capitalized terms that are used in this Agreement but not
defined herein (other than the names of Plans) shall have the meanings set forth
in the Separation Agreement, and, as used herein, the following terms shall have
the following meanings (such meanings to be equally applicable to both the
singular and plural forms of the terms defined):

                                      -16-
<PAGE>

         AGCO EMPLOYEE: as of the Separation Date, any individual who is
classified as an AgCo Employee under Section 1.1(a), and thereafter, any
individual who is, at the relevant time, an Employee of any member of the AgCo
Group.

         AGCO EMPLOYEE BENEFIT PLAN: any AgCo Plan that is an Employee Benefit
Plan.

         AGCO ESOP LOAN:  defined in Section 2.3(d).

         AGCO ESOP SECURITY:  defined in Section 2.3(d).

         AGCO FORMER EMPLOYEE: any individual who is classified as an AgCo
Former Employee under Section 1.2 and any individual who is an AgCo Employee on
or after the Separation Date and who has, before the relevant time, ceased to be
an AgCo Employee, other than as a result of a Transfer.

         AGCO GROUP: the Monsanto Group as defined in the Separation Agreement.

         AGCO PARTICIPANT: any individual who is an AgCo Employee, an AgCo
Former Employee, or a Beneficiary of such an individual.

         AGCO PENSION PLAN:  defined in Section 2.1(b)(i).

         AGCO PLAN: any Plan sponsored by one or more members of the AgCo Group.

         AGCO SEPARATION PAY PLAN:  defined in Section 1.3(b).

         AGCO SIP:  defined in Section 2.3(b).

         AGCO SIP TRUST:  defined in Section 2.3(b).

         AGCO 2000 RETIREE WELFARE PLAN:  defined in Section 2.5(b).

         AGREEMENT: this Employee Benefits and Compensation Allocation
Agreement, including the Schedules, in each case as amended and supplemented in
accordance with the terms hereof.

         ALTERNATE PAYEE: an alternate payee under a domestic relations order
which has been determined by the appropriate Plan administrator to be qualified
under Section 414(p) of the Code and Section 206(d) of ERISA and that creates or
recognizes an alternate payee's right to, or assigns to an alternate payee, all
or a portion of the benefits payable to a participant under any Plan, or an
alternate recipient under a medical child support order that has been determined
by the appropriate Plan administrator to be qualified under Section 609(a) of
ERISA and that creates or recognizes the existence of an alternate recipient's
right to, or assigns to an alternate recipient the right to, receive benefits
for which a participant or beneficiary is eligible under any Plan.

         ASSIGNED SPLIT DOLLAR POLICIES:  defined in Section 2.5(d).

         AUDIT LIABILITY:  defined in Section 4.3(a).

                                      -17-
<PAGE>

         BENEFICIARY: a beneficiary, dependent or Alternate Payee of a
participant in a Plan or the estate of a deceased participant in a Plan, in each
case, in his, her or its capacity as such a beneficiary, dependent, Alternate
Payee or estate.

         CODE: the Internal Revenue Code of 1986, as amended, and the Treasury
Regulations promulgated thereunder.

         ELIGIBLE EARNINGS: "Eligible Earnings" as defined in the Monsanto SIP,
except that base pay shall be determined as of the Separation Date, annual
incentive compensation shall be deemed to equal the annual incentive opportunity
at outstanding performance as in effect on the Separation Date, and overtime and
shift differentials shall be deemed to equal the overtime and shift
differentials for the calendar year 1999.

         EMPLOYEE: with respect to any entity, an individual who is considered,
according to the payroll and other records of such entity, to be employed by
such entity, regardless of whether such individual is, at the relevant time,
actively at work or on leave of absence (including vacation, holiday, sick
leave, family and medical leave, disability leave, military leave, jury duty,
layoff with rights of recall, and any other leave of absence or similar
interruption of active employment that is not considered, according to the
policies or practices of such entity, to have resulted in a permanent
termination of such individual's employment by reason of long-term disability or
otherwise).

         EMPLOYEE BENEFIT PLAN: any Plan that is an "employee benefit plan"
within the meaning of Section 3(3) of ERISA (whether or not such Plan is subject
to ERISA).

         EMPLOYER SECURITIES: shares of common stock of Pharmacia that are held
in the Monsanto SIP immediately before the Separation Date.

         ENROLLED ACTUARY: Towers Perrin or another enrolled actuary selected by
AgCo with the approval of Pharmacia, which approval shall not be unreasonably
withheld.

         ERISA: the Employee Retirement Income Security Act of 1974, as amended,
or any successor legislation, and the regulations promulgated thereunder.

         ESOP FINANCED SHARES: shares of Employer Securities that were acquired
with the proceeds of any loans pursuant to the terms of Section 19 of the
Monsanto SIP or the corresponding provisions of the AgCo SIP.

         ESOP FRACTION: the ratio of the Eligible Earnings of all AgCo Employees
who are participating in the Monsanto SIP as of the relevant date to the
Eligible Earnings of all Employees who are participating in the Monsanto SIP as
of the relevant date. For purposes of any Audit Liability described in Section
4.3(a)(iii) that is imposed before the SIP Transfer Date, the relevant date
shall be the last day of the month immediately before the month in which such
Audit Liability is imposed, and for all other purposes, the relevant date shall
be the SIP Transfer Date.

         EXISTING MONSANTO ESOP SECURITY: any unpaid portion of (a) the
promissory note entered into on December 16, 1991 between Pharmacia and the
Monsanto SIP Trust, (b)

                                      -18-
<PAGE>

the 7.09% Guaranteed Amortizing ESOP Notes due December 15, 2000 issued by the
Monsanto SIP Trust, and (c) and the 8.13% Guaranteed Amortizing ESOP Debentures
due December 15, 2006 issued by the Monsanto SIP Trust.

         FOREIGN PLAN: any Plan maintained outside of the United States
primarily for the benefit of individuals substantially all of whom are
nonresident aliens with respect to the United States, other than the TCN Policy.

         FOUNDATION EMPLOYEE: an individual who is, immediately before the
Separation Date, a Monsanto Employee in a corporate staff position that supports
both the Agriculture Business and the Pharmacia Business.

         GROUP: the AgCo Group, the Monsanto Group, or the Pharmacia Group, as
the context requires.

         HOST GROUP: with respect to each country set forth in Schedule II,
either the AgCo Group or the Pharmacia Group, as indicated in Schedule II.

         INVESTMENT COMMITTEE: defined in Section 4.6(c).

         IPO: defined in the recitals.

         JOINT ADMINISTRATIVE COMMITTEE: defined in Section 4.6(f).

         MERGER: the Merger of MP Sub, Incorporated with and into Pharmacia &
UpJohn, Inc. on March 31, 2000, as contemplated by the Merger Agreement.

         MERGER AGREEMENT: the Agreement and Plan of Merger among Monsanto
Company, MP Sub, Incorporated and Pharmacia & Upjohn, Inc. dated as of December
19, 1999, as amended.

         MONSANTO EMPLOYEE: an individual who is an Employee of any member of
the Pharmacia Group or the AgCo Group immediately before the Separation Date and
who either (i) was an Employee of a member of the Monsanto Group immediately
before the Merger or (ii) was hired after the Merger but before the Separation
Date in a position such that he or she was eligible to participate in one or
more of the Old Monsanto Plans.

         MONSANTO EMPLOYEE BENEFITS PLAN COMMITTEE: defined in Section 4.6(d).

         MONSANTO FOREIGN FORMER EMPLOYEES: any Monsanto Former Employee as to
whom the Plans providing him or her with benefits are primarily Foreign Plans.

         MONSANTO FORMER EMPLOYEE: any individual who is not, as of the
Separation Date, a Monsanto Employee but who was a Monsanto Employee at any time
before the Separation Date, and who is, as of the Separation Date, entitled to
any benefits (whether or not contingent and whether or not currently in pay
status) under any Old Monsanto Plan or under any Monsanto Individual
Supplemental Retirement Agreement.

                                      -19-
<PAGE>

         MONSANTO GROUP: the corporation now known as Pharmacia (then known as
Monsanto Company) and its Subsidiaries, as they existed before the consummation
of the Merger on March 31, 2000.

         MONSANTO INDIVIDUAL SUPPLEMENTAL RETIREMENT AGREEMENT: any agreement
between any member of the Monsanto Group and any single Employee or former
Employee of any member of the Monsanto Group providing for post-retirement
income, pension or welfare benefits (other than pursuant to a Welfare Plan, a
Qualified Plan, a Monsanto Non-Qualified Pension Plan, the Monsanto SIP Parity
Plan or the TCN Policy).

         MONSANTO INTERNAL PEOPLE COMMITTEE: defined in Section 4.6(d).

         MONSANTO NON-QUALIFIED PENSION PLANS: the Monsanto Company ERISA Parity
Pension Plan, the Monsanto Company Supplemental Retirement Plan, and any
successors thereto.

         MONSANTO PENSION PLAN: the Monsanto Company Pension Plan and any
successor thereto, other than the AgCo Pension Plan.

         MONSANTO RETIREE LIFE INSURANCE PLAN: the Monsanto Company Salaried and
Non-Union Hourly Retiree Group Life Insurance Plan, consisting of the 1971,
1976, 1981, 1986, 1991, 1995, DeKalb and Searle/Nutrasweet Subplans.

         MONSANTO RETIREE MEDICAL PLAN: the Monsanto Company Salaried and
Non-Union Hourly Retirees' Medical Benefits Plan, consisting of the 1971, 1976,
1981, 1986, 1991, 1995, DeKalb and Searle/Nutrasweet Subplans.

         MONSANTO RETIREE WELFARE PLANS: the Monsanto Retiree Life Insurance
Plan and the Monsanto Retiree Welfare Plan.

         MONSANTO SEPARATION PLAN: the Monsanto Company Salaried and Non-Union
Hourly Employees' Separation Plan.

         MONSANTO SIP: the Monsanto Savings and Investment Plan and any
successor thereto, other than the AgCo SIP.

         MONSANTO SIP PARITY PLAN: the Monsanto Company ERISA Parity Savings and
Investment Plan and any successor thereto, other than a Plan sponsored by one or
more members of the AgCo Company.

         MONSANTO SIP TRUST: the Monsanto Company Defined Contribution and
Employee Stock Ownership Trust and any successor thereto, other than the AgCo
SIP Trust.

         MONSANTO U.S. FORMER EMPLOYEES: any Monsanto Former Employee who is not
a Monsanto Foreign Former Employee.

                                      -20-
<PAGE>

         MONSANTO U.S. WELFARE PLAN: any Welfare Plan of one or more members of
the Monsanto Group that is a U.S. Plan, but excluding Severance Plans.

         NEW MONSANTO ESOP SECURITY: defined in Section 2.3(d).

         NEW PHARMACIA U.S. WELFARE PLANS: defined in Section 2.5(a).

         OLD MONSANTO PLANS: those Plans that were, immediately before the
Merger, sponsored by any member of the Monsanto Group.

         OVERSIGHT COMMITTEE: defined in Section 4.6(b).

         PBGC: the Pension Benefit Guaranty Corporation.

         PENSION TRANSFER DATE: defined in Section 2.1(b)(i).

         PHARMACIA: defined in the preamble.

         PHARMACIA ADMINISTRATIVE COMMITTEE - U.S. PLANS: defined in Section
4.6(e).

         PHARMACIA EMPLOYEE: as of the Separation Date, any individual who is
classified as a Pharmacia Employee under Section 1.1(a) and thereafter, any
individual who becomes, on or before the relevant date, an Employee of any
member of the Pharmacia Group in a position such that he or she is eligible to
participate in any Old Monsanto Plans.

         PHARMACIA EMPLOYEE BENEFIT PLAN: any Pharmacia Plan that is an Employee
Benefit Plan.

         PHARMACIA FORMER EMPLOYEE: any individual who is classified as a
Pharmacia Former Employee under Section 1.2, and any individual who is a
Pharmacia Employee on or after the Separation Date and who has, as of the
relevant time, ceased to be a Pharmacia Employee, other than as a result of a
Transfer.

         PHARMACIA PARTICIPANT: any individual who is a Pharmacia Employee, a
Pharmacia Former Employee, or a Beneficiary of such an individual.

         PHARMACIA PLAN: any Plan sponsored by a member of the Pharmacia Group.

         PHARMACIA RETAINED RETIREE LIFE INSURANCE SUBPLANS: the
Searle/Nutrasweet Subplan of the Monsanto Retiree Life Insurance Plan, the 1995
Subplan of the Monsanto Retiree Life Insurance Plan, and any successors thereto.

         PHARMACIA RETAINED RETIREE MEDICAL SUBPLANS: the Searle/Nutrasweet
Subplan of the Monsanto Retiree Medical Plan, the 1995 Subplan of the Monsanto
Retiree Medical Plan, and any successors thereto.

         PHARMACIA RETAINED RETIREE WELFARE SUBPLANS: the Pharmacia Retained
Retiree Life Insurance Subplans and the Pharmacia Retained Retiree Medical
Subplans.

                                      -21-
<PAGE>

         PLAN: any written or unwritten plan, policy, program, payroll practice,
ongoing arrangement, trust, fund, contract, insurance policy or other agreement
or funding vehicle provided by, contributed to or sponsored by one or more
members of the AgCo Group or the Monsanto Group, providing benefits to AgCo
Participants or Pharmacia Participants, regardless of whether it is mandated
under local law or negotiated or agreed to as a term or condition of employment
or otherwise, and regardless of whether it is governmental, private, funded,
unfunded, financed by the purchase of insurance, contributory or
noncontributory, but excluding individual agreements.

         SEPARATION AGREEMENT: defined in the recitals.

         SEVERANCE LIABILITIES: all Liabilities in respect of severance,
redundancy and similar pay, salary continuation, and similar obligations
relating to the termination or alleged termination of any such individual's
employment, whether or not arising under a Severance Plan, but excluding
Liabilities under individual employment agreements.

         SEVERANCE PLAN: defined in Section 1.3(a).

         SIP TRANSFER DATE: defined in Section 2.3(b).

         SPLIT DOLLAR LIFE INSURANCE PROGRAM: the Monsanto Company Executive
Life Insurance Program, including all individual life insurance contracts, split
dollar agreements and collateral assignments thereunder.

         TCN POLICY: the Monsanto Company Third Country National Policy.

         TRANSFER: the transfer of a Transferred Employee from the AgCo Group to
the Pharmacia Group or from the Pharmacia Group to the AgCo Group, as
applicable.

         TRANSFERRED EMPLOYEE: a Monsanto Employee who is an AgCo Employee or a
Pharmacia Employee immediately before the Separation Date and who, at any time
within one year after the Separation Date, becomes a Pharmacia Employee or an
AgCo Employee, respectively, by agreement of AgCo and Pharmacia.

         U.S. WELFARE PLAN: any Welfare Plan that is a U.S. Plan.

         U.S.: the fifty states of the United States of America.

         U.S. PLAN: any Plan that is not a Foreign Plan.

         TRANSFER VALUE: defined in Schedule III.

         WELFARE PLAN: any Foreign Plan or U.S. Plan that is an "employee
welfare benefit plan," as defined in Section 3(1) of ERISA, whether or not such
plan is subject to ERISA.

                                      -22-
<PAGE>

                  IN WITNESS WHEREOF, the parties have caused this Agreement to
be duly executed as of the day and year first above written.

                              PHARMACIA CORPORATION

                              By:   /s/ Christopher J. Coughlin
                                   ---------------------------------------------
                                    Christopher J. Coughlin
                                    Executive Vice President and Chief
                                    Financial Officer

                             MONSANTO COMPANY

                              By:   /s/ Hendrik A. Verfaillie
                                   ---------------------------------------------
                                    Hendrik A. Verfaillie
                                    President and Chief Executive Officer

                                      -23-<PAGE>

                                                                    EXHIBIT 10.8

                    INTELLECTUAL PROPERTY TRANSFER AGREEMENT

                                 BY AND BETWEEN

                             PHARMACIA CORPORATION,

                             A DELAWARE CORPORATION

                                       AND

                                MONSANTO COMPANY

                             A DELAWARE CORPORATION

                             as of SEPTEMBER 1, 2000
<PAGE>

<TABLE>
<CAPTION>
                                                         TABLE OF CONTENTS

ARTICLE                                                                                                                 PAGE
----------------------------------------------------------------------------------------------------------------------------

<S>                                                                                                                     <C>
I.       DEFINITIONS......................................................................................................2

II.      TRANSFER OF MONSANTO TECHNOLOGY.................................................................................11

III.     TRANSFER OF MONSANTO BUSINESS TECHNOLOGY AGREEMENTS.............................................................22

IV.      TRANSFER OF MONSANTO TRADEMARKS.................................................................................23

V.       TRANSFER OF MONSANTO COPYRIGHTS.................................................................................25

VI.      TRANSFER OF MONSANTO EMPLOYEE AGREEMENTS .......................................................................26

VII.     LICENSE TO PHARMACIA OF MONSANTO TECHNOLOGY.....................................................................26

VIII.    LICENSE TO MONSANTO OF PHARMACIA TECHNOLOGY ....................................................................27

IX.      TRANSITIONAL LICENSE TO MONSANTO OF PHARMACIA TRADEMARKS........................................................28

X.       EXPORT REGULATIONS..............................................................................................29

XI.      CONFIDENTIALITY.................................................................................................29

XII.     NOTICES.........................................................................................................31

XIII.    ASSIGNABILITY AND CONSENTS......................................................................................32

XIV.     GOVERNING LAW...................................................................................................34

XV.      MISCELLANEOUS...................................................................................................34
</TABLE>

                                       i
<PAGE>

                                TABLE OF EXHIBITS

EXHIBIT NO.                   SUBJECT MATTER
-------------------------------------------------------------------------------

1       SCHEDULE OF PATENTS, PATENT APPLICATIONS, AND
        INVENTION DISCLOSURES, BY CLASSIFICATION

2       ASSIGNMENT OF UNITED STATES MONSANTO PATENT RIGHTS

3       ASSIGNMENT OF MONSANTO KNOW-HOW

4       ASSIGNMENT OF MONSANTO BUSINESS TECHNOLOGY AGREEMENTS

5       ASSIGNMENT OF MONSANTO TRADEMARKS

6       ASSIGNMENT OF MONSANTO COPYRIGHTS

7       ASSIGNMENT OF MONSANTO EMPLOYEE AGREEMENTS

8       MONSANTO TECHNOLOGY LICENSE AGREEMENT

9       PHARMACIA TECHNOLOGY LICENSE AGREEMENT

10      TRADEMARK LICENSE AGREEMENT

                                       ii
<PAGE>

                    INTELLECTUAL PROPERTY TRANSFER AGREEMENT

         INTELLECTUAL PROPERTY TRANSFER AGREEMENT, dated as of September 1,
2000, by and between Pharmacia Corporation, a Delaware corporation,
("Pharmacia"), and Monsanto Company, a newly-formed Delaware corporation, which
is a wholly-owned subsidiary of Pharmacia having a place of business at 800
North Lindbergh Blvd., St. Louis, Missouri 63167-("Monsanto").

                              W I T N E S S E T H:

         WHEREAS, Pharmacia and Monsanto executed a Separation Agreement to
transfer into Monsanto certain of the businesses currently owned and conducted
by Pharmacia directly and through certain of its subsidiaries;

         WHEREAS, Pharmacia and Monsanto agreed in the Separation Agreement to
execute instruments of assignment and transfer to Monsanto all of the right,
title, and interest of the Pharmacia Group in the Monsanto;

         WHEREAS, the Monsanto Assets to be transferred to Monsanto pursuant to
the Separation Agreement include Monsanto Intellectual Property; and,

         WHEREAS, Pharmacia and Monsanto have determined that it is necessary
and desirable to effect the transfer of Monsanto Intellectual Property to
Monsanto;

                                       1
<PAGE>

         NOW, THEREFORE, in furtherance of the transfers and assignments set
forth in the Separation Agreement and in consideration of the mutual agreements
and covenants hereinafter set forth, the parties hereby agree as follows:

                             ARTICLE I - DEFINITIONS

1.0      Capitalized terms used herein, but not defined herein, shall have
         meanings ascribed to such terms as set forth in the Separation
         Agreement, which are hereby incorporated by reference. In addition for
         purposes of this Intellectual Property Transfer Agreement and the
         assignments and agreements attached hereto, the following terms shall
         have the meanings set forth below (such meanings to be equally
         applicable to both the singular and plural forms of the terms defined):

         1.1      MONSANTO BUSINESS: as used in this Intellectual Property
                  Transfer Agreement and in the assignments and agreements
                  attached hereto as exhibits, shall mean (i) all businesses and
                  operations (including related joint ventures and alliances) of
                  the agricultural businesses of Pharmacia as described in the
                  IPO Registration Statement and as conducted on the Separation
                  Date, consisting principally of those businesses and
                  operations set forth on Schedule M-5 of the Separation
                  Agreement conducted by the Agricultural Unit and (ii) any
                  other business or operation on the Separation Date conducted
                  by or for the Agricultural Unit of the former "Monsanto
                  Company" prior to the merger with Pharmacia & UpJohn through
                  the ownership or use of the Monsanto Assets, as well as all
                  businesses and operations referred to in the definition of
                  Former Agricultural Business set forth in the Separation
                  Agreement. For the sake of clarity, the products listed below
                  will not be considered to be part of Monsanto Business: Cox-2
                  Inhibitors whether synthetic or naturally-occurring; IBAT
                  (ASBT) inhibitors whether synthetic or naturally-occurring;
                  Naxcel/Excenel Sterile Powder 4 gram (ceftiofur; antibiotic);

                                       2
<PAGE>

                  Excenel RTU Sterile Suspension 5 gram (ceftiofur; antibiotic);
                  MGA Premix (Melengestrol Acetate; estrus suppression);
                  Lutalyse Sterile Suspension (dinoprost tromethamine; estrus
                  synchronization); Linco-Spectin Premix (66%) (mixture of
                  lincomycin and spectinomycin; antibiotic); Lincomix Feed
                  Additive 44 (mixture of lincomycin and spectinomycin;
                  antibiotic); Pirsue Aqueous Gel (pirlimycin; antibiotic);
                  Linco-Spectin Premix (44%) (mixture of lincomycin and
                  spectinomycin; antibiotic); Lincomix 110 (mixture of
                  lincomycin and spectinomycin; antibiotic); Depo Medrol
                  (methylprednisone acetate; treatment of musculoskeletal
                  conditions); Quartermaster (penicillin/dihydrostreptomycin;
                  antibiotic); Winstrol V Injection (stanozolol; anabolic
                  steroid to improve appetite, promote weight gain, increase
                  strength and vitality); Naxcel/Excenel Sterile Powder 1 gram
                  J-5 E.coli bacteria (ceftiofur; antibiotic) Lincomix
                  injectible 300 mg/ml (mixture of lincomycin and spectinomycin;
                  antibiotic); Lutalyse 10 ml (dinoprost tromethamine; estrus
                  synchronization); UNIPRIM/TUCOPRIM 150 (trimethoprim and
                  sulfadiazine; antibiotic); Linco-Spectin SS 100 ml (mixture of
                  lincomycin and spectinomycin; antibiotic); Mitaban Liquid
                  Concentrate (amitraz liquid concentrate; treatment of
                  demodicosis in dogs) Adspec Sterile Suspension (spectinomycin
                  sulfate; antibiotic); Lincocin Forte Solution (lincomycin;
                  antibiotic) and Hylartin (sodium hyaluronate; treatment of
                  equine arthritis).

         1.2      MONSANTO BUSINESS TECHNOLOGY AGREEMENTS: shall mean all
                  contracts which pertain to intellectual property, technology,
                  or Information that is primarily applicable to the Monsanto
                  Business, to which Pharmacia or a Subsidiary or Affiliate
                  thereof is a party, including without limitation patent
                  licenses, technology licenses, immunities from suit,
                  settlement agreements, rights to grant licenses or to
                  sublicense, agreements whereby Third Parties have become
                  obligated to keep

                                       3
<PAGE>

                  confidential Information belonging to Pharmacia or a
                  Subsidiary of Pharmacia, and agreements between Pharmacia or a
                  Subsidiary of Pharmacia and Third Parties with respect to the
                  confidentiality of Information belonging to such Third
                  Parties.

         1.3      MONSANTO COPYRIGHTS: shall mean all Copyrights that are
                  primarily applicable to the Monsanto Business.

         1.4      MONSANTO EMPLOYEE: shall mean any individual who (1)
                  immediately prior to the Separation Date is an officer or
                  employee of any member of the Monsanto Group or the Pharmacia
                  Group and (a) is primarily employed in the Monsanto Business
                  or (b) will be an officer or employee of the Monsanto Group
                  immediately following the Separation Date or (2) were
                  primarily employed by Monsanto during the 2 year period before
                  the Separation Date and were not employed elsewhere in
                  Pharmacia during that period.

         1.5      MONSANTO EMPLOYEE AGREEMENTS: shall mean all agreements
                  between Pharmacia or its Subsidiaries and Monsanto Employees
                  regarding the employment of such Monsanto Employees by
                  Pharmacia or one of its Subsidiaries.

         1.6      MONSANTO INTELLECTUAL PROPERTY: shall mean any and all
                  Monsanto Technology, Monsanto Trademarks, and Monsanto
                  Copyrights.

         1.7      MONSANTO KNOW-HOW: shall mean and include without limitation
                  all information, inventions and discoveries made prior to the
                  Separation Date that relate primarily to the Monsanto Business
                  (including but not limited to inventions and discoveries
                  disclosed in patents, patent applications or invention
                  disclosures as listed in Classes 1 and 3 in the schedule
                  attached hereto as Exhibit 1, with such changes as may be
                  agreed to in writing by Pharmacia and Monsanto, and made a
                  part hereof), Know-How primarily relating to the areas of
                  technology to which such inventions and

                                       4
<PAGE>

                  discoveries are directed, and all other Know-How relating
                  primarily to the Monsanto Business.

         1.8      MONSANTO PATENT RIGHTS: shall mean all United States and
                  foreign patents and all United States, Patent Cooperation
                  Treaty ("PCT"), and foreign patent applications (both
                  provisional and non-provisional) owned by Pharmacia or a
                  Subsidiary of Pharmacia as of the Separation Date, which are
                  primarily applicable to the Monsanto Business (including but
                  not limited to patents and patent applications listed in
                  Classes 1 and 3 in the schedule attached hereto as Exhibit 1,
                  with such changes as may be agreed to in writing by Pharmacia
                  and Monsanto, and made a part hereof). Any patents or patent
                  applications of any country or jurisdiction that are
                  counterparts of patents or patent applications listed in Class
                  1 or 3 of Exhibit 1 and that may erroneously or inadvertently
                  be omitted from Class 1 or 3 of Exhibit 1 shall be deemed to
                  be listed therein.

         1.9      MONSANTO PROPRIETARY BUSINESS INFORMATION: shall mean all
                  business Information of a confidential, trade secret, and/or
                  proprietary nature primarily applicable to the Monsanto
                  Business, including without limitation all cost Information,
                  sales and pricing data, customer prospect lists, supplier
                  records, customer and supplier lists, customer and vendor
                  data, correspondence, and lists, product literature, art work,
                  design, development, and manufacturing files, vendor and
                  customer drawings, formulations and specifications, quality
                  records and reports, lists of advertisers, records pertaining
                  to advertisers and accounts, and other books, records,
                  studies, surveys, reports, plans, and document forms and any
                  other business information primarily applicable to the
                  Monsanto Business.

                                       5
<PAGE>

         1.10     MONSANTO TECHNOLOGY: shall mean any and all Monsanto Know-How
                  and Monsanto Patent Rights.

         1.11     MONSANTO TRADEMARKS: shall mean all trade names, registered
                  and unregistered trademarks, service marks, service names, and
                  trade styles, which belong to Pharmacia and are primarily
                  applicable to the Monsanto Business.

         1.12     COPYRIGHTS: shall mean all statutory, common law, and
                  registered copyrights in computer programs and other software,
                  product literature, labels, artwork, and other advertising
                  materials, engineering drawings, operating, maintenance, and
                  instructional manuals, and any other original works of
                  authorship, which are owned by, or licensed to, Pharmacia or a
                  subsidiary of Pharmacia, as of the Separation Date.

         1.13     SEPARATION AGREEMENT: shall mean the Separation Agreement
                  dated as of September 1, 2000, between Pharmacia and Monsanto
                  to effect the allocation of assets and liabilities between
                  Pharmacia and Monsanto.

         1.14     KNOW-HOW: shall mean all trade secrets, research and
                  development Information, research and technology reports,
                  research notebooks and files, formulations, chemical library
                  information, such as that in the Sample Research Center
                  relating to experimental compounds and formulations including
                  but not limited to "CP" and "SC" compounds, manufacturing and
                  environmental procedures and Information, drawings of plants,
                  equipment and apparatus, analytical methods and laboratory
                  procedures, raw material and product specifications, operating
                  manuals, pilot plant Information, library materials, software,
                  databases and computer programs, financial, accounting,
                  management, information technology, human resources, and other
                  business systems and practices, improvements, formulae,
                  practices,

                                       6
<PAGE>

                  processes, methods and other know-how, whether or not
                  patentable, to the extent owned by, or licensed to, Pharmacia
                  or a Subsidiary of Pharmacia, as of the Separation Date.

         1.15     PHARMACEUTICALS BUSINESS: all businesses and operations
                  (including related joint ventures and alliances) of all
                  segments of Pharmacia as conducted on the Separation Date not
                  constituting part of the Monsanto Business. For the sake of
                  clarity, non-human somatotropins are not be considered to be
                  part of the Pharmaceutical Business.

         1.16     PHARMACEUTICALS COPYRIGHTS: shall mean all Copyrights that are
                  not Monsanto Copyrights.

         1.17     PHARMACEUTICALS KNOW-HOW: shall mean all inventions and
                  discoveries made prior to the Separation Date that are not
                  Monsanto Know-Know (including but not limited to inventions
                  and discoveries disclosed in patents, patent applications or
                  invention disclosures as listed in Classes 2 and 4 in the
                  schedule attached hereto as Exhibit 1, with such changes as
                  may be agreed to in writing by Pharmacia and Monsanto, and
                  made a part hereof), Know-How relating to the areas of
                  technology to which such inventions and discoveries are
                  directed, and all other Know-How which is not Monsanto
                  Know-How.

         1.18     PHARMACIA COPYRIGHTS: shall mean all Pharmaceuticals
                  Copyrights and Shared Copyrights retained by Pharmacia.

         1.19     PHARMACIA EMPLOYEE: shall mean any individual who at any time
                  prior to the Separation Date is or was an officer or employee
                  of any member of the Monsanto Group or the Pharmacia Group,
                  other than Monsanto Employees.

                                       7
<PAGE>

         1.20     PHARMACIA EMPLOYEE AGREEMENTS: shall mean all agreements
                  between Pharmacia or its Subsidiaries and Pharmacia Employees
                  regarding the employment of such Pharmacia Employees by
                  Pharmacia or one of its Subsidiaries.

         1.21     PHARMACIA INTELLECTUAL PROPERTY: shall mean any and all
                  Pharmacia Technology, Pharmacia Trademarks, and Pharmacia
                  Copyrights.

         1.22     PHARMACIA KNOW-HOW: shall mean all Pharmaceuticals Know-How
                  and Shared Know-How retained by Pharmacia.

         1.23     PHARMACIA PATENT RIGHTS: shall mean all United States and
                  foreign patents and all United States, PCT, and foreign patent
                  applications (both provisional and nonprovisional), owned by
                  Pharmacia or an Affiliate or Subsidiary of Pharmacia as of the
                  Separation Date, which are not Monsanto Patent Rights
                  (including but not limited to patents and patent applications
                  listed in Classes 2 and 4 in the schedule attached hereto as
                  Exhibit 1, with such changes as may be agreed to in writing by
                  Pharmacia and Monsanto, and made a part hereof). Exhibit 1
                  lists only a extremely limited number of Class 2 patents,
                  patent applications, and invention disclosures that are being
                  retained by Pharmacia with no rights therein being conveyed or
                  licensed to Monsanto. The Class 2 items that are listed in
                  Exhibit 1 are included only to indicate that their
                  classification was considered and decided in the preparation
                  of Exhibit 1. All of the substantial number of other United
                  States and foreign patents and United States, PCT, and foreign
                  patent applications (both provisional and nonprovisional),
                  owned by Pharmacia or an affiliate of Pharmacia as of the
                  Separation Date, which are not listed in Exhibit 1 or a later
                  addendum to Exhibit 1 agreed to in writing by Pharmacia and
                  Monsanto, are to be treated as Class 2 items with no rights
                  therein being conveyed or licensed to Monsanto.

                                       8
<PAGE>

         1.24     PHARMACIA PROPRIETARY BUSINESS INFORMATION: shall mean all of
                  Pharmacia's business Information of a confidential, trade
                  secret, and/or proprietary nature, including without
                  limitation all cost Information, sales and pricing data,
                  customer prospect lists, supplier records, customer and
                  supplier lists, customer and vendor data, correspondence, and
                  lists, product literature, art work, design, development, and
                  manufacturing files, vendor and customer drawings,
                  formulations and specifications, quality records and reports,
                  lists of advertisers, records pertaining to advertisers and
                  accounts, and other books, records, surveys, reports, plans,
                  and document forms, and any other business information to the
                  extent owned or otherwise controlled by Pharmacia as of the
                  Separation Date and which are not Monsanto Proprietary
                  Business Information.

         1.25     PHARMACIA TECHNOLOGY: shall mean any and all Pharmacia Patent
                  Rights and Pharmacia Know-How.

         1.26     PHARMACIA TRADEMARKS: shall mean all trade names, registered
                  and unregistered trademarks, service marks, service names, and
                  trade styles which are not Monsanto Trademarks and which
                  Pharmacia will license to Monsanto.

         1.27     SHARED COPYRIGHTS: shall mean Copyrights that are either
                  Monsanto Copyrights or Pharmaceuticals Copyrights that are
                  useful or potentially useful in both the Monsanto Business and
                  the Pharmaceuticals Business, including but not limited to
                  those which are generally applicable to manufacturing,
                  environmental, safety or control, engineering, plant equipment
                  and operation, process control, analytical systems, quality
                  control, maintenance, safety systems, transportation,
                  management, or financial, business, or information technology
                  systems.

                                       9
<PAGE>

         1.28     SHARED KNOW-HOW: shall mean Know-How that is either Monsanto
                  Know-How or Pharmaceuticals Know-How useful or potentially
                  useful in both the Monsanto Business and the Pharmaceuticals
                  Business, including but not limited to that which is generally
                  applicable to manufacturing, environmental safety or control,
                  engineering, plant equipment and operation, process control,
                  analytical systems, quality control, maintenance, safety
                  systems, transportation, management, or financial, business,
                  or information technology systems.

         1.29     THIRD PARTY: shall mean any Person, other than a member of the
                  Pharmacia Group or a member of the Monsanto Group.

         1.30     THIRD PARTY KNOW-HOW LICENSES: shall mean any know-how rights
                  owned by a Third Party, not primarily applicable to the
                  Pharmaceuticals Business, not covered by a Monsanto Business
                  Technology Agreement and with respect to which Pharmacia or a
                  Subsidiary of Pharmacia is licensed and given the right to
                  sublicense a Subsidiary, Affiliate, or other entity or the
                  right to assign a portion of its license pertaining to a
                  particular business or filed of use to a Subsidiary,
                  Affiliate, or other entity.

         1.31     THIRD PARTY PATENT LICENSES: shall mean any patent rights
                  owned by a Third Party, not primarily applicable to the
                  Pharmaceuticals Business, not covered by a Monsanto Business
                  Technology Agreement, and with respect to which Pharmacia or a
                  Subsidiary of Pharmacia is licensed and given the right to
                  sublicense a Subsidiary, Affiliate, or other entity or the
                  right to assign a portion of its license pertaining to a
                  particular business or filed of use to a Subsidiary,
                  Affiliate, or other entity.

                                       10
<PAGE>

1.32              INTELLECTUAL PROPERTY shall mean all patents, patent
                  applications, invention disclosures, trademarks, copyrights
                  and Know-How owned by either party as of the date of the
                  Separation Agreement, and rights related thereto acquired
                  under any existing agreement with a third party.

                  ARTICLE II - TRANSFER OF MONSANTO TECHNOLOGY

2.0      The classifications indicated in Exhibit 1 entitled "Schedule of
         Patents, Patent Applications, and Invention Disclosures" shall include
         the following classes (which may be referenced herein by Class number)
         with the following meanings, subject to further definition and
         limitation pursuant to this Intellectual Property Transfer Agreement:

         Class                           Description
         -----      -----------------------------------------------------

            1       Assigned to Monsanto, with no rights retained by
                    Pharmacia.

            2       Retained by Pharmacia, with no rights conveyed or
                    licensed to Monsanto. (See the definition of
                    Pharmacia Patent Rights set forth in Article I for
                    information regarding Class 2 items listed in the
                    Exhibit 1 Schedule)

            3       Assigned to Monsanto, with a royalty-free license
                    granted to Pharmacia pursuant to Article VII hereof.

            4       Retained by Pharmacia, with a royalty-free license
                    granted to Monsanto pursuant to Article VIII hereof.

         The parties agree that for three (3) years following the Separation
         Date, they will rectify by mutual agreement any bona fide mistakes or
         oversights which may have been made regarding the disposition of any
         Intellectual Property including any bona fide mistakes or oversights
         which may have been made in the classification of any patent, patent

                                       11
<PAGE>

         application or invention disclosure in Exhibit 1 or any portion thereof
         incorporated into any schedule in any of the agreements exhibited to
         this Intellectual Property Transfer Agreement.

2.1      The parties agree that transfers of Monsanto Technology made pursuant
         to the Separation Agreement by Pharmacia to Monsanto shall comprise all
         worldwide right, title, and interest in and to Monsanto Technology
         (subject to the grant by Monsanto to Pharmacia of a royalty-free,
         worldwide license for the use of certain Monsanto Patent Rights
         pursuant to Article VII hereof) and shall be delivered to Monsanto as
         soon as is reasonably practicable on or after the Separation Date. The
         parties further agree that all costs associated with the transfers of
         Monsanto Technology set forth in this Intellectual Property Transfer
         Agreement including without limitation recordation of any assignment
         and name change documents shall be borne by Pharmacia or the relevant
         entity of the Pharmacia Group.

2.2      Monsanto Patent Rights in the United States of America shall be
         formally assigned by Pharmacia to Monsanto or a designated Subsidiary
         of Monsanto pursuant to the ASSIGNMENT OF UNITED STATES MONSANTO PATENT
         RIGHTS, as set forth substantially in the form to be executed which is
         attached hereto as Exhibit 2, with such changes as may be agreed to in
         writing by Pharmacia and Monsanto. Pharmacia covenants and agrees that
         its employees, attorneys, or other representatives will timely execute,
         whenever requested by Monsanto and without additional cost to Monsanto,
         all applications, assignments, lawful oaths, and any other papers which
         Monsanto may deem necessary or desirable for securing to Monsanto or
         for maintaining for Monsanto any of the rights being formally assigned
         by Pharmacia to Monsanto in the ASSIGNMENT OF UNITED STATES MONSANTO
         PATENT RIGHTS.

2.3      Pharmacia agrees to cause relevant entities of the Pharmacia Group to
         execute an ASSIGNMENT OF UNITED STATES MONSANTO PATENT RIGHTS,
         generally in the form set forth in

                                       12
<PAGE>

         Exhibit 2 attached hereto, with such changes as may be agreed to in
         writing by Pharmacia and Monsanto, but with different schedules
         identifying the patents and patent applications being assigned.
         Pharmacia agrees to cause relevant entities of the Pharmacia Group to
         require their employees, attorneys, or other representatives to timely
         execute, whenever requested by Monsanto and without additional cost to
         Monsanto, all applications, assignments, lawful oaths, and any other
         papers which Monsanto may deem necessary or desirable for securing to
         Monsanto or for maintaining for Monsanto any of the rights to be
         formally assigned pursuant to this section 2.3.

2.4      Pharmacia hereby authorizes Monsanto, its successors and assigns, to
         file applications for Letters Patent in any foreign country or
         jurisdiction corresponding to the Letters Patent of Schedule 2 in
         Exhibit 2 and the applications for Letters Patent of Schedule 2 in
         Exhibit 2 and to secure in its own name the Letters Patent issued
         thereon, the same to be held and enjoyed by Monsanto, its successors
         and assigns, for the full term for which such Letters Patent are
         granted or may be extended, as fully and entirely as the same would
         have been held and enjoyed by Pharmacia had the Monsanto Patent Rights
         not been assigned to Monsanto.

2.5      Additional instruments of assignment sufficient for purposes of
         recordation or registration relating to patents and patent applications
         in countries other than the United States which are included in the
         Monsanto Patent Rights shall be promptly provided to Monsanto by
         Pharmacia or the relevant entity of the Pharmacia Group, by means of
         good and sufficient recordable instruments of assignment applicable to
         such countries. The cost of providing any and all such assignment
         instruments and for effecting recordal thereof in all countries shall
         be borne by Pharmacia or the relevant entity of the Pharmacia Group and
         accomplished as promptly as is reasonable.

                                       13
<PAGE>

2.6      To the extent that Monsanto prepares, files, prosecutes, or maintains,
         or causes others to prepare, file, prosecute, or maintain, patents or
         patent applications (either provisional or non-provisional) included in
         the Monsanto Patent Rights, Pharmacia, relevant entities of the
         Pharmacia Group, and their respective directors, officers, employees
         and agents shall reasonably cooperate in the preparation, filing,
         prosecution, and maintenance thereof, by providing Monsanto with data
         and information within their possession after the Separation Date which
         may be needed or requested by Monsanto and by executing all documents
         that Monsanto or a relevant entity in the Monsanto Group may deem
         necessary.

2.7      To the extent that Pharmacia prepares, files, prosecutes, or maintains,
         or causes others to prepare, file, prosecute, or maintain, patents or
         patent applications (either provisional or non-provisional) included in
         the Pharmacia Patent Rights, Monsanto, relevant entities of the
         Monsanto Group, and their respective directors, officers, employees and
         agents shall reasonably cooperate in the preparation, filing,
         prosecution, and maintenance thereof, by providing Monsanto with data
         and information within their possession after the Separation Date which
         may be needed or requested by Pharmacia and by executing all documents
         that Pharmacia or a relevant entity of the Pharmacia Group may deem
         necessary.

2.8      Monsanto Know-How included in the Monsanto Technology shall be formally
         assigned by Pharmacia to Monsanto pursuant to the ASSIGNMENT OF
         MONSANTO KNOW-HOW, as set forth substantially in the form to be
         executed which is attached hereto as Exhibit 3, with such changes as
         may be agreed to in writing by Pharmacia and Monsanto.

2.9      Pharmacia agrees to cause the relevant entities of the Pharmacia Group
         to execute an ASSIGNMENT OF MONSANTO KNOW-HOW, generally in the form
         set forth in Exhibit 3 attached hereto, with such changes as may be
         agreed in writing by Pharmacia and

                                       14
<PAGE>

         Monsanto, but with different schedules identifying the Monsanto
         Know-How being assigned.

2.10     To the extent that Monsanto prepares, files, or prosecutes, or causes
         others to prepare, file, or prosecute patent applications (either
         provisional or non-provisional) based upon inventions, discoveries,
         trade secrets, or other know-how included in the Monsanto Know-How,
         Pharmacia, relevant entities of the Pharmacia Group, and their
         respective directors, officers, employees and agents shall reasonably
         cooperate in the preparation, prosecution, and maintenance thereof, by
         providing Monsanto with data and information within their possession as
         of the Separation Date which may be needed or requested by Monsanto and
         by executing all documents that Monsanto or a relevant entity in the
         Monsanto Group may deem necessary.

2.11     To the extent that Pharmacia prepares, files, or prosecutes, or causes
         others to prepare, file, or prosecute patent applications (either
         provisional or non-provisional) based upon inventions, discoveries,
         trade secrets, or other know-how included in the Pharmacia Know-How,
         Monsanto, relevant entities of the Monsanto Group, and their respective
         directors, officers, employees and agents shall reasonably cooperate in
         the preparation, prosecution, and maintenance thereof, by providing
         Pharmacia with data and information within their possession after the
         Separation Date which may be needed or requested by Pharmacia and by
         executing all documents that Pharmacia or a relevant entity in the
         Pharmacia Group may deem necessary.

2.12     With respect to any patent or patent application prepared, filed,
         prosecuted or maintained pursuant to Section 2.6 or 2.10 hereof, in the
         event that Monsanto or the relevant entity of the Monsanto Group
         decides to allow any patent or patent application in Class 3 to lapse
         or become abandoned or decides to allow a Class 3 provisional patent
         application to become abandoned without filing a non-provisional patent
         application claiming priority

                                       15
<PAGE>

         from said Class 3 provisional application, Pharmacia or the relevant
         entity of the Pharmacia Group shall first and promptly be provided an
         opportunity to prosecute and maintain said Class 3 patent or patent
         application or to file a non-provisional patent application claiming
         priority from said Class 3 provisional application. If Pharmacia or the
         relevant entity of the Pharmacia Group decides to undertake such
         filing, prosecution, or maintenance, said Class 3 patent or patent
         application shall be reassigned to the relevant entity of the Pharmacia
         Group without additional cost. Such reassignment shall be subject to a
         worldwide, nonexclusive, royalty-free license to Monsanto and relevant
         entities of the Monsanto Group to use all patent rights being
         reassigned. Monsanto, relevant entities of the Monsanto Group, and
         their respective employees shall reasonably cooperate with Pharmacia in
         the prosecution and maintenance thereof by providing Pharmacia with
         data and information within their possession as of the date of
         reassignment which may be needed and by executing all documents that
         Pharmacia or a relevant entity in the Pharmacia Group may deem
         necessary.

2.13     With respect to any patent or patent application prepared, filed,
         prosecuted, or maintained pursuant to Section 2.7 or 2.11 hereof, in
         the event that Pharmacia or the relevant entity of the Pharmacia Group
         decides to allow any patent or patent application in Class 4 to lapse
         or become abandoned or decides to allow a Class 4 provisional patent
         applications to become abandoned without filing a non-provisional
         patent application claiming priority from said Class 4 provisional
         application, Monsanto or the relevant entity of the Monsanto Group
         shall first and promptly be provided an opportunity to prosecute and
         maintain said Class 4 patent or patent application or to file a
         non-provisional patent application claiming priority from said Class 4
         provisional application. If Monsanto or the relevant entity of the
         Monsanto Group decides to undertake such filing, prosecution, or
         maintenance, said Class 4 patent or patent application shall be
         assigned to the relevant entity of the Monsanto Group without
         additional cost. Such assignment shall be subject to a

                                       16
<PAGE>

         worldwide, nonexclusive, royalty-free license to Pharmacia and relevant
         entities of the Pharmacia Group to use all patent rights being so
         assigned. Pharmacia, relevant entities of the Pharmacia Group, and
         their respective employees shall reasonably cooperate with Monsanto in
         the prosecution and maintenance thereof by providing Monsanto with data
         and information within their possession as of the date of assignment
         which may be needed and by executing all documents that Monsanto or a
         relevant entity in the Monsanto Group may deem necessary.

2.14     Neither the provisions of Sections 2.12 or 2.13 nor any other
         provisions of this Intellectual Property Transfer Agreement shall
         require either party to prepare, file, prosecute, defend, enforce or
         maintain, any patent or patent application, owned by such party after
         the Separation Date or based upon an invention, discovery, or trade
         secret included in the Know-How owned by such party after the
         Separation Date, regardless of whether the other party is or would be
         licensed under such patent or patent application pursuant to a license
         granted under this Intellectual Property Transfer Agreement.

2.15     Pharmacia and Monsanto agree to the disposition and treatment of
         Information, documents, records, and materials (collectively referred
         to as "Materials") containing Know-How which is either assigned or
         licensed to Monsanto by Pharmacia pursuant to this Intellectual
         Property Transfer Agreement as follows:

         (a)      In accordance with Section 2.18 below, all Materials relating
                  to Monsanto Technology shall be provided to Monsanto to the
                  extent they are not commingled with Materials relating to
                  Pharmacia Technology;

         (b)      Initially, research notebooks generated by the former Monsanto
                  Company other than those produced and kept by G.D. Searle
                  (hereinafter referred to as "Red

                                       17
<PAGE>

                  Notebooks") will remain in the custody of Monsanto Company. If
                  either Pharmacia or Monsanto makes a request for a Red
                  Notebook or information contained in a specific Red Notebook,
                  a determination will be made as to whether such Red Notebook
                  contains only Pharmacia Know-How, only Monsanto Know-How,
                  predominantly Pharmacia Know-How, or predominantly Monsanto
                  Know-How. Upon the request of Pharmacia for a particular Red
                  Notebook, custody of such Red Notebook shall be transferred to
                  Pharmacia in those cases where the subject Red Notebook
                  contains only Pharmacia Know-How, or predominantly Pharmacia
                  Know-How. Regardless of which party has custody of a subject
                  Red Notebook, custody shall not adversely affect the rights of
                  the non-custodial party in the Know-How contained therein and
                  the custodial party shall make any such Notebook containing
                  the Know-how of the non-custodial party reasonably available
                  as circumstances by require.

         (c)      Except to the extent set forth in 2.15(b) above or where the
                  Separation Team of Section 2.18 should decide otherwise, in
                  those instances where Materials relating to Monsanto
                  Technology are commingled with Materials relating to Pharmacia
                  Technology (E.G., research reports, technical reports,
                  analytical reports, engineering reports, microfilmed records,
                  and the like) or where Materials relate to Shared Know-How,
                  Monsanto shall retain such Materials in compliance with its
                  Record Management Retention Guidelines and provide Monsanto
                  with access thereto and, if requested by Monsanto, with copies
                  thereof during the period of time such Information and
                  Materials are so maintained. In the event that originals of
                  such Materials are needed by Monsanto (E.G., for discovery or
                  evidentiary use in litigation or administrative proceedings),
                  Pharmacia shall make such originals available to Monsanto.

                                       18
<PAGE>

2.16     Pharmacia agrees that it will not assert any patent it owns as of the
         Separation Date or may own within five (5) years thereof against any
         product that Monsanto was selling, offering for sale, leasing and/or
         importing as of the Separation Date.

2.17     Monsanto agrees that it will not assert any patent it owns as of the
         Separation Date or may own within five (5) years thereof against any
         product that Pharmacia was selling, offering for sale, leasing and/or
         importing as of the Separation Date.

2.18     (a) Monsanto and Pharmacia agree to cooperate in the determination as
         to which party is to be assigned Intellectual Property, including
         Know-How, not specifically assigned by any schedule, list or exhibit
         herein. To that end each party shall appoint one or more members to a
         team, hereinafter referred to as the "Separation Team", that will meet
         with each other and determine within two (2) years of the Separation
         Date which party is to have ownership, possession and/or any other
         rights to such Intellectual Property including any tangible Know-How
         records. Regardless of the number of people appointed to the Separation
         Team, Monsanto and Pharmacia shall each have a single vote in making
         any decision. In the event of any dispute that cannot be resolved by
         the Separation Team, the dispute will resolved in accordance with the
         procedures of Section 15.3 herein.

         (b) It is agreed that each party is to take possession of its
         Intellectual Property including any tangible Know-How. In the event
         that some records or other information cannot be reasonably split such
         that each party can take possession of its records, the Separation Team
         shall determine which party shall maintain possession and the procedure
         regarding access to the records by the other party.

         (c) Pharmacia shall retain all right, title and interest in and to the
         inventory of compounds stored in the Sample Retention Center ("SRC")
         existing within Monsanto sites

                                       19
<PAGE>

         in St. Louis at Separation Date. In accordance with Pharmacia having
         all incidents of ownership in the SRC, Pharmacia shall have exclusive
         and absolute rights of possession, control and disposition of all SRC
         compounds. Monsanto shall have no rights of access to SRC compounds
         with this EXCEPTION: Monsanto shall have an absolute license and access
         to a sample of any compound for (i) a compound(s) which as of the
         Separation Date has (have) been incorporated into a formulation
         targeted for evaluation in a field plot or is or has been a
         commercialized product of Monsanto or which is a metabolite of such
         product, or (ii) for a compound or material that is the subject of an
         inquiry from a regulatory agency.

         (d) In the event Monsanto requests a sample of an SRC compound beyond
         the scope of the EXCEPTION articulated in Section 2.18 (c), herein,
         Pharmacia shall have sole discretion as to whether Pharmacia shall
         provide such sample of SRC compound to Monsanto, as well as the amount
         of such sample. Rights of ownership and access of SRC compounds by
         Pharmacia or Monsanto, as set forth in Section 2.18 (c), herein, as
         well as requests from Monsanto for sample access beyond the scope of
         the EXCEPTION stated herein, shall not be subject to consideration by
         the Separation Team.

         (e) Notwithstanding anything to the contrary, the database information
         containing chemical structure and biological data for any and all
         compounds, including but not limited to SRC compounds, made by or on
         behalf of the Agricultural Unit of Pharmacia and assayed for
         agricultural-related activity shall be considered Shared Know-How.
         Pursuant to Articles VII and VIII both Pharmacia and Monsanto shall
         have an irrevocable, royalty-free, worldwide license to such Shared
         Know-How. However, the parties recognize that exploitation of such
         Shared Know-How by either party in their respective business field has
         the potential to adversely affect the value of such Shared Know-How to
         the other party. Accordingly, the parties agree to negotiate in good
         faith with the goal to reach

                                       20
<PAGE>

         mutually acceptable terms under which such Shared Know-How may be
         used. If the parties are unsuccessful in negotiating such terms, such
         dispute will resolved in accordance with the procedures of Section 15.3
         herein.

         (f) It is recognized that prior to the Separation Date, all right,
         title and interest in and to all Intellectual Property resided in
         Pharmacia, subject to assignment and license obligations set forth in
         this Intellectual Property Transfer Agreement. In event of any dispute
         as to the assignment and/or license obligations with respect to a
         selected item of Intellectual Property, ownership, possession and
         control of the subject Intellectual Property not yet assigned or
         licensed to Monsanto, as the case may be, shall reside in Pharmacia.
         During the pendency of any such dispute and until any assignment or
         license to Monsanto is formally effected, Pharmacia shall maintain any
         and all involved Intellectual Property in a manner which will not
         diminish the value of such Intellectual Property to Monsanto. Issues
         raised as to resolution of such dispute shall be decided in accordance
         with the provisions of Section 15.3, herein.

         (g) The effect of any specific provision of this Intellectual Property
         Transfer Agreement as to disposition of a specific property shall take
         precedent over and not be altered by the content, scope or definition
         of more general terms such as "Know-how" or "Intellectual Property".

2.19     Both Pharmacia and Monsanto shall have the obligation to offer the
         other party a license for use in the other party's business field and
         to conduct good faith negotiations with respect to a royalty-bearing
         license on commercially-reasonably terms to any technology developed
         within two (2) years of the Separation Date which has been shown or is
         reasonably anticipated to have application in the other party's
         business field.

                                       21
<PAGE>

        ARTICLE III - TRANSFER OF MONSANTO BUSINESS TECHNOLOGY AGREEMENTS

3.1      All rights held by Pharmacia as of the Separation Date in Monsanto
         Business Technology Agreements shall be formally assigned by Pharmacia
         to Monsanto or a designated Subsidiary of Monsanto pursuant to the
         ASSIGNMENT OF MONSANTO BUSINESS TECHNOLOGY AGREEMENTS, as set forth
         substantially in the form to be executed which is attached hereto as
         Exhibit 4, with such changes as may be agreed to in writing by
         Pharmacia and Monsanto.

3.2      Pharmacia agrees to cause the relevant entities of the Pharmacia Group
         to execute an ASSIGNMENT OF MONSANTO BUSINESS TECHNOLOGY AGREEMENTS,
         generally in the form set forth in Exhibit 4 attached hereto, with such
         changes as may be agreed to in writing by Pharmacia and Monsanto, to
         assign to Monsanto or a Subsidiary of Monsanto any Monsanto Business
         Technology Agreements to which a Subsidiary of Pharmacia is a party.

3.3      Any royalties or other payments which Pharmacia or a Subsidiary of
         Pharmacia shall incur pursuant to the terms of the Monsanto Business
         Technology Agreements to be assigned shall be prorated as of the
         Separation Date, based on actual days elapsed, with appropriate debits
         and credits to the accounts of Pharmacia or the Subsidiary of Pharmacia
         and Monsanto or a Subsidiary of Monsanto, so that Monsanto or the
         Subsidiary of Monsanto shall be responsible for all such payments to
         the extent duly allocable to the period commencing on the Separation
         Date.

3.4      Any royalties or other payments which Pharmacia or a Subsidiary of
         Pharmacia shall be entitled to receive from Third Parties pursuant to
         the terms of Monsanto Business Technology Agreements to be assigned
         shall be prorated as of the Separation Date, based

                                       22
<PAGE>

         on actual days elapsed, with appropriate debits and credits to the
         accounts of Pharmacia or the Subsidiary of Pharmacia and Monsanto or a
         Subsidiary of Monsanto, so that Monsanto or the Subsidiary of Monsanto
         shall be entitled to receive all such payments to the extent duly
         allocable to the period commencing on the Separation Date.

                  ARTICLE IV - TRANSFER OF MONSANTO TRADEMARKS

4.1      The parties agree that the transfer of Monsanto Trademarks made
         pursuant to the Separation Agreement by Pharmacia to Monsanto shall
         comprise all worldwide right, title, and interest in and to Monsanto
         Trademarks and shall be delivered to Monsanto as soon as is reasonably
         practicable on or after the Separation Date. The parties further agree
         that all costs associated with the transfer of Monsanto Trademarks set
         forth in this Intellectual Property Transfer Agreement shall be borne
         by Pharmacia or the relevant entity of the Group.

4.2      Monsanto Trademarks for which registrations exist, or have been applied
         for, in the United States of America shall be formally assigned by
         Pharmacia to Monsanto or its designee pursuant to the ASSIGNMENT OF
         MONSANTO TRADEMARKS, as set forth substantially in the form to be
         executed, which is attached hereto as Exhibit 5 with such changes as
         may be agreed to in writing by Pharmacia and Monsanto. Pharmacia
         covenants and agrees that its employees, attorneys, or other
         representatives will timely execute, whenever reasonably requested by
         Monsanto and without additional cost to Monsanto, all applications,
         assignments, lawful oaths, and any other papers which Monsanto may deem
         necessary or desirable for securing to Monsanto or (at Chemical's
         expense) for maintaining for Monsanto any of the rights being formally
         assigned by Pharmacia to Monsanto in the ASSIGNMENT OF MONSANTO
         TRADEMARKS.

                                       23
<PAGE>

4.3      Pharmacia agrees to cause relevant Pharmacia Subsidiaries to execute an
         ASSIGNMENT OF MONSANTO TRADEMARKS, generally in the form set forth in
         Exhibit 5 attached hereto, with such changes as may be agreed to in
         writing by Pharmacia and Monsanto, but with different schedules
         identifying the trademarks rights being assigned. Pharmacia agrees to
         cause relevant entities of the Pharmacia Group to require their
         employees, attorneys, or other representatives to timely execute,
         whenever reasonably requested by Monsanto and without additional cost
         to Monsanto, all applications, assignments, lawful oaths, and other
         papers which Monsanto may deem necessary or desirable for securing to
         Monsanto or for maintaining for Monsanto any of the rights to be
         formally assigned pursuant to this section 4.3.

4.4      Additional instruments of assignment sufficient for purposes of
         recordation or registration relating to trademark rights in countries
         other than the United States which are included in the Monsanto
         Trademarks shall be promptly provided to Monsanto by Pharmacia or the
         relevant entity of the Pharmacia Group, by means of good and sufficient
         recordable instruments of assignment applicable to such countries. The
         cost of providing any and all such assignment instruments and for
         effecting recordal thereof in all countries shall be borne by Pharmacia
         or the relevant entity of the Pharmacia Group and accomplished as
         promptly as is reasonable after the Separation Date.

                   ARTICLE V - TRANSFER OF MONSANTO COPYRIGHTS

5.1      The parties agree that the transfer of Monsanto Copyrights made
         pursuant to the Separation Agreement by Pharmacia to Monsanto shall
         comprise all worldwide right, title, and interest in and to Monsanto
         Copyrights and shall be delivered to Monsanto as soon as reasonably
         practicable on or after the Separation Date. The parties further agree
         that all costs associated with the transfer of Monsanto Copyrights set
         forth in this Intellectual

                                       24
<PAGE>

         Property Transfer Agreement shall be borne by Pharmacia or the relevant
         entity of the Pharmacia Group.

5.2      Monsanto Copyrights shall be formally assigned by Pharmacia to Monsanto
         pursuant to the ASSIGNMENT OF MONSANTO COPYRIGHTS, as set forth
         substantially in the form to be executed, which is attached hereto as
         Exhibit 6, with such changes as may be agreed to in writing by
         Pharmacia and Monsanto. Pharmacia covenants and agrees that its
         employees, attorneys, or other Representatives will timely execute,
         whenever reasonably requested by Monsanto and without additional cost
         to Monsanto, all applications, assignments, lawful oaths, and any other
         papers which Monsanto may deem necessary or desirable for securing to
         Monsanto or (at Chemical's expense) maintaining for Monsanto any of the
         rights being formally assigned by Pharmacia to Monsanto in the
         ASSIGNMENT OF MONSANTO COPYRIGHTS.

5.3      Pharmacia agrees to cause relevant Pharmacia Subsidiaries to execute an
         ASSIGNMENT OF MONSANTO COPYRIGHTS, generally in the form set forth in
         Exhibit 6 attached hereto, with such changes as may be agreed to in
         writing by Pharmacia and Monsanto. Pharmacia agrees to cause relevant
         entities of the Pharmacia Group to require their employees, attorneys,
         or other representatives to timely execute, whenever reasonably
         requested by Monsanto and without additional cost to Monsanto, all
         applications, assignments, lawful oaths, and other papers which
         Monsanto may deem necessary or desirable for securing to Monsanto or
         (at Chemical's expense) for maintaining for Monsanto any of the rights
         to be formally assigned pursuant to this section 5.3.

              ARTICLE VI - TRANSFER OF MONSANTO EMPLOYEE AGREEMENTS

6.1      Rights relating to the Monsanto Business held by Pharmacia as of the
         Separation Date in Monsanto Employee Agreements and Pharmacia Employee
         Agreements shall be formally

                                       25
<PAGE>

         assigned and granted by Pharmacia to Monsanto pursuant to the
         ASSIGNMENT OF MONSANTO EMPLOYEE AGREEMENTS, as set forth substantially
         in the form to be executed which is attached hereto as Exhibit 7, with
         such changes as may be agreed to in writing by Pharmacia and Monsanto.

6.2      Pharmacia agrees to cause relevant entities of the Pharmacia Group to
         execute an ASSIGNMENT OF MONSANTO EMPLOYEE AGREEMENTS, generally in the
         form set forth in Exhibit 7 attached hereto, with such changes as may
         be agreed to in writing by Pharmacia and Monsanto, to assign and grant
         to Monsanto or a Subsidiary of Monsanto rights relating to the Monsanto
         Business held by a Subsidiary of Pharmacia in any Monsanto Employee
         Agreements or Pharmacia Employee Agreements.

            ARTICLE VII - LICENSE TO PHARMACIA OF MONSANTO TECHNOLOGY

7.1      Monsanto agrees to execute a MONSANTO TECHNOLOGY LICENSE AGREEMENT as
         set forth substantially in the form to be executed, which is attached
         hereto as Exhibit 8, with such changes as may be agreed to in writing
         by Pharmacia and Monsanto, whereby Pharmacia shall be granted an
         irrevocable, royalty-free, worldwide license, with right to
         sub-license, to utilize the Monsanto Patent Rights in Class 3, the
         inventions described in the invention disclosures in Class 3, Know-How
         related to such patent rights or inventions, and any Shared Know-How
         and Shared Copyrights held by Monsanto, as further set forth in Exhibit
         8.

7.2      Monsanto agrees to cause relevant entities of the Monsanto Group to
         execute a MONSANTO TECHNOLOGY LICENSE AGREEMENT generally in the form
         set forth in Exhibit 8 attached hereto, with such changes as may be
         agreed to in writing by Pharmacia and Monsanto, but with different
         schedules identifying the patents, patent applications, and invention
         disclosures being licensed, whereby the relevant entity of the
         Pharmacia Group

                                       26
<PAGE>

         shall be granted an irrevocable, royalty-free, worldwide license to
         utilize Monsanto Patent Rights in Class 3, the inventions described in
         the invention disclosures in Class 3, Know-How related to such patent
         rights or inventions, and any Shared Know-How and Shared Copyrights
         held by the relevant entity of the Monsanto Group, as further set forth
         generally in Exhibit 8.

           ARTICLE VIII - LICENSE TO MONSANTO OF PHARMACIA TECHNOLOGY

8.1      All right, title, and interest in and to Pharmacia Patent Rights and
         Pharmacia Know-How shall remain with Pharmacia, except to the extent
         licensed to Monsanto pursuant to this Article VIII, and Pharmacia shall
         remain free to otherwise transfer, license, or utilize Pharmacia Patent
         Rights and Pharmacia Know-How at its sole discretion.

8.2      Pharmacia agrees to execute a PHARMACIA TECHNOLOGY LICENSE AGREEMENT as
         set forth substantially in the form to be executed which is attached
         hereto as Exhibit 9, with such changes as may be agreed to in writing
         by Pharmacia and Monsanto, whereby Monsanto shall be granted an
         irrevocable, royalty-free, worldwide license, with right to
         sub-license, to utilize the Pharmacia Patents Rights in Class 4,
         inventions described in the invention disclosures in Class 4, Know-How
         related to such patent rights or inventions, and Shared Know-How and
         Shared Copyrights retained by Pharmacia, as further set forth in
         Exhibit 9.

8.3      Pharmacia also agrees that in the PHARMACIA TECHNOLOGY LICENSE
         AGREEMENT, Pharmacia shall assign to Monsanto the right to utilize
         within the Monsanto Business all rights to Third Party Patent Licenses
         and Third Party Know-How Licenses available to Pharmacia or shall grant
         to Monsanto a sublicense to utilize outside the Pharmaceuticals
         Business all rights in Third Party Patent Licenses and Third Party
         Know-How Licenses available to Pharmacia, as further set forth in
         Exhibit 9.

                                       27
<PAGE>

8.4      Pharmacia agrees to cause relevant entities of the Pharmacia Group to
         execute a PHARMACIA TECHNOLOGY LICENSE AGREEMENT, generally in the form
         set forth in Exhibit 9 attached hereto, with such changes as may be
         agreed to in writing by Pharmacia and Monsanto, but with different
         schedules identifying the patent rights and know-how rights being
         licensed, whereby the relevant entity of the Monsanto Group shall be
         granted an irrevocable, royalty-free, worldwide license to utilize
         Pharmacia Patent Rights in Class 4, the inventions described in the
         invention disclosures in Class 4, Know-How related to such patent
         rights or inventions, and Shared Know-How and Shared Copyrights held by
         the relevant entity of the Pharmacia Group, as further set forth in
         Exhibit 9.

      ARTICLE IX - TRANSITIONAL LICENSE TO MONSANTO OF PHARMACIA TRADEMARKS

9.1      Pharmacia agrees to execute a TRADEMARK LICENSE AGREEMENT, as set forth
         substantially in the form to be executed, which is attached hereto as
         Exhibit 10, with such changes as may be agreed to in writing by
         Pharmacia and Monsanto.

9.2      All right, title, and interest in and to the Pharmacia Trademarks shall
         remain with Pharmacia, except to the extent licensed for the
         transitional period pursuant to the TRADEMARK LICENSE AGREEMENT, and
         Pharmacia shall remain free to otherwise transfer, license, or utilize
         Pharmacia Trademarks at its sole discretion.

                         ARTICLE X - EXPORT REGULATIONS

10.1     Notwithstanding any other provisions of this Intellectual Property
         Transfer Agreement, Monsanto agrees, and agrees to cause entities in
         the Monsanto Group to agree, to make no disclosure or use of any
         Monsanto Technology, Pharmacia Technology, or Information derived from
         Monsanto Business Technology Agreements, provided or made known to the
         Monsanto Group pursuant to this Intellectual Property Transfer
         Agreement, except in

                                       28
<PAGE>

         compliance with the laws and regulations of the United States of
         America, including the Bureau of Export Administration, International
         Trade Commission, U.S. Department of Commerce, U.S. Department of the
         Treasury, and U.S. Department of State.

                          ARTICLE XI - CONFIDENTIALITY

11.1     Except as provided in Section 11.2 hereof or as the parties hereto may
         otherwise agree in writing, from and after the Separation Date, (a)
         Pharmacia shall not use without authority of Monsanto any Intellectual
         Property or other information that hereinafter belongs to Monsanto and
         to which a right to use has not been conveyed to Pharmacia by operation
         of this Intellectual Property Transfer Agreement, (b) Monsanto shall
         not use without authority of Pharmacia any Intellectual Property or
         other information that hereinafter belongs to Pharmacia and to which a
         right to use has not been conveyed to Monsanto by operation of this
         Intellectual Property Transfer Agreement, and (c) Pharmacia and
         Monsanto shall each hold and use its reasonable best efforts to cause
         its Affiliates and Representatives to hold in strict confidence all
         Intellectual Property and other information which hereinafter belongs
         to the other party and to which a right to use has not been conveyed to
         it by operation of this Intellectual Property Transfer Agreement

11.2     The obligations set forth in this Article XI shall not apply to the
         extent that:

         (a)  disclosure of such Information is compelled by judicial or
              administrative process or, in the opinion of such party's counsel,
              by other requirements of law, or

         (b)  such party can show that such Information was:

                  (1)     available to such party after the Separation Date from
                          third party sources other than employees or former
                          employees of either party, their Affiliates,

                                       29
<PAGE>

                          former Affiliates, Representatives or former
                          Representatives, on a nonconfidential basis prior to
                          its disclosure to such party after the Separation Date
                          by the other party,

                  (2)     in the public domain through no fault of such party,

                  (3)     lawfully acquired by such party from third party
                          sources other than employees or former employees of
                          either party, their Affiliates, former Affiliates,
                          Representatives or former Representatives, after the
                          time that it was furnished to such party pursuant to
                          this Intellectual Property Transfer Agreement or the
                          assignments or agreements attached hereto as exhibits,
                          or

                  (4)     independently discovered or developed by employees of
                          such party.

11.3     Notwithstanding the foregoing, each of Pharmacia and Monsanto shall be
         deemed to have satisfied its obligations under this Article XI with
         respect to any Information if it exercises the same care with regard to
         such Information as it takes to preserve confidentiality for its own
         similar Information.

11.4     The obligations set forth in this Article XI shall continue to apply
         with respect to both Pharmacia and Monsanto for as long as the
         Information to be held in confidence remains confidential without
         breach of the obligations hereof.

11.5     With respect to Shared Know-How each party shall have the right, in the
         pursuit of business in its respective field, to use and/or disclose
         such Shared Know-How to third parties in confidence under terms that
         are comparable to those herein. Each party shall also have the right to
         disclose such Shared Know-How information in the normal course of
         filing and prosecuting a patent application.

                                       30
<PAGE>

                              ARTICLE XII - NOTICES

12.1     All notices, requests, claims, demands and other communications
         hereunder (collectively, "Notices") shall be in writing and shall be
         given (and shall be deemed to have been duly given upon receipt) by
         delivery in person, by cable, telegram, facsimile, electronic mail or
         other standard form of telecommunications (provided confirmation is
         delivered to the recipient the next business day in the case of
         facsimile, electronic mail or other standard form of
         telecommunications) or by registered or certified mail, postage
         prepaid, return receipt requested, addressed as follows:

                  If to Pharmacia:          Pharmacia Corporation
                                            100 Route 206 North
                                            Peapack, New Jersey  07977
                                            Attention:  Christopher J. Coughlin
                                            Telephone:  (908) 901-8000
                                            Facsimile:

                                       31
<PAGE>

                  with a copy to:           Pharmacia Corporation
                                            100 Route 206 North
                                            Peapack, New Jersey  07977
                                            Attention:  General Counsel
                                            Telephone:  (908) 901-8000
                                            Facsimile:

                  If to Monsanto:           Monsanto Company
                                            800 North Lindbergh Boulevard
                                            St. Louis, Missouri  63167
                                            Attention:  Terrence Crews
                                            Telephone:  (314) 694-1000
                                            Facsimile:

                  with a copy to:           Monsanto Company
                                            800 North Lindbergh Boulevard
                                            St. Louis, Missouri  63167
                                            Attention:  General Counsel
                                            Telephone:  (314) 694-1000
                                            Facsimile:

         or to such other address as any party hereto may have furnished to the
         other parties by a notice in writing in accordance with this Section
         12.1.

                    ARTICLE XIII - ASSIGNABILITY AND CONSENTS

13.1     This Intellectual Property Transfer Agreement and all of the provisions
         hereof shall be binding upon and inure to the benefit of the parties
         hereto and their successors and assigns. Neither this Intellectual
         Property Transfer Agreement nor any of the rights, interests and
         obligations hereunder shall be assigned by any party hereto without
         first notifying the other party. Consent to such assignment shall not
         be required.

13.2     This Intellectual Property Transfer Agreement is solely for the benefit
         of the parties hereto and their Subsidiaries and Affiliates and is not
         intended to confer upon any other Persons any rights or remedies
         hereunder.

                                       32
<PAGE>

13.3     Nothing contained in this Intellectual Property Transfer Agreement
         shall be construed as an attempt or an agreement to assign, transfer,
         or license any Monsanto Technology, Pharmacia Technology, Monsanto
         Copyrights, Pharmacia Copyrights, Monsanto Business Technology
         Agreement, Shared Know-How, Third Party Patent Licenses, or Third Party
         Know-How Licenses, which cannot be assigned, transferred, or licensed
         without the consent of a Third Party (hereinafter referred to as
         "Transfer Requiring Consent"), unless such consent shall have been
         given. Pharmacia shall use its reasonable best efforts and bear the
         costs to obtain all such necessary consents.

13.4     If efforts to obtain the consent of a Third Party to any Transfer
         Requiring Consent, or if any attempted Transfer Requiring Consent,
         would be ineffective or would adversely affect the rights of Pharmacia
         or an entity of the Pharmacia Group so that Monsanto would not, in
         fact, receive the rights of the agreement under which Transfer
         Requiring Consent is sought, then Pharmacia or such entity of the
         Pharmacia Group, as the case may be, shall cooperate in any reasonable
         arrangement Monsanto may request to provide for Monsanto the rights
         sought to be transferred by such Transfer Requiring Consent, including
         enforcement for the benefit of Monsanto of the rights of Pharmacia or
         such entity of the Pharmacia Group against any Third Party arising out
         of the breach or cancellation by such Third Party of the agreement
         under which Transfer Requiring Consent is sought; provided that
         Pharmacia or such entity of the Pharmacia Group shall not be required
         to incur any costs or obligations, other than nominal administrative
         costs or ministerial duties of a usual and customary nature, in
         connection with any such reasonable arrangement and that no such
         arrangement shall interfere with Pharmacia's conduct of its business or
         have an adverse effect on the financial condition or business of
         Pharmacia.

                                       33
<PAGE>

                           ARTICLE XIV - GOVERNING LAW

14.1     With the exception of those subjects or disputes which are within the
         exclusive jurisdiction of statutes of the United States or other
         countries, including their respective patent laws, this Intellectual
         Property Transfer Agreement shall be governed by and construed in
         accordance with the laws of the State of Delaware (other than the laws
         regarding choice of laws and conflicts of laws) as to all matters,
         including matters of validity, construction, effect, performance, and
         remedies.

                           ARTICLE XV - MISCELLANEOUS

15.1     Pharmacia and Monsanto undertake and agree, and agree to cause their
         respective Groups to agree, to assist each other, to the extent such
         cooperation is needed, in the registration or recordation of any
         assignment or transfer made, or license granted, in accordance with
         this Intellectual Property Transfer Agreement, in the manner provided
         for under the laws and regulations of the countries involved, including
         but not limited to the execution of any additional patent, trademark,
         copyright, or know-how assignments or license agreements that may be
         required for such registration or recordal purposes. All costs
         associated with such assignments or license agreements and the
         registration or recordation thereof shall be borne by Pharmacia or the
         relevant entity of the Pharmacia Group.

15.2     Any provision of this Intellectual Property Transfer Agreement which is
         prohibited or unenforceable in any jurisdiction shall, as to such
         jurisdiction, be ineffective to the extent of such prohibition or
         unenforceability without invalidating the remaining provisions hereof.
         Any such prohibition or unenforceability in any jurisdiction shall not
         invalidate or render unenforceable such provision in any other
         jurisdiction. Each party acknowledges that money damages would be an
         inadequate remedy for any breach of the provisions of

                                       34
<PAGE>

         this Intellectual Property Transfer Agreement and agrees that the
         obligations of the parties hereunder shall be specifically enforceable.

15.3     All disputes, controversies, or claims (whether sounding in contract,
         tort, or otherwise) that may arise out of or relate to, or arise under
         or in connection with this Intellectual Property Transfer Agreement or
         any of the assignments or license agreements included as Exhibits
         hereto, or the transactions contemplated hereby or thereby, shall be
         governed by the procedures set forth in Article VI of the Separation
         Agreement.

15.4     All Exhibits (and any appendices thereto) referred to in this
         Intellectual Property Transfer Agreement are hereby incorporated in and
         made an integral part hereof.

15.5     The Article headings contained in this Intellectual Property Transfer
         Agreement are solely for the purpose of reference, are not part of the
         agreement of the parties hereto, and shall not in any way affect the
         meaning or interpretation of this Intellectual Property Transfer
         Agreement.

15.6     References to any "Article," "Exhibit," "Schedule," or "Section"
         without more, are to Articles, Exhibits, Schedules, or Sections to or
         of this Intellectual Property Transfer Agreement. Unless otherwise
         expressly stated, clauses beginning with the term "including" set forth
         examples only and in no way limit the generality of the matters thus
         exemplified.

15.7     (a) Except as set forth in the Separation Agreement, together with all
         documents and agreements to be delivered pursuant hereto or in
         connection herewith, this Intellectual Property Transfer Agreement
         constitutes the entire agreement between the parties with respect to
         the subject matter hereof and shall supersede all previous
         negotiations, commitments, and writings with respect to such subject
         matter. Except as set forth in Section 15.7 (b) below in the event of
         any conflict between this Intellectual Property

                                       35
<PAGE>

         Transfer Agreement and the Separation Agreement, the terms and
         conditions of this Intellectual Property Transfer Agreement shall be
         controlling. In the event of any conflict between this Intellectual
         Property Transfer Agreement and any of the assignments or agreements
         attached hereto as Exhibits, the terms and conditions of the assignment
         or agreement attached hereto as an Exhibit shall be controlling.

         (b) Monsanto and Pharmacia are involved in certain research and
         development collaborations which extend beyond the Separation Date. It
         is understood and agreed that the disposition of any intellectual
         property derived in accordance with said collaborations will be agreed
         upon separately from this Intellectual Property Transfer agreement or
         in accordance with agreements in force as of the date of this
         Intellectual Property Transfer Agreement. In the event of any conflict
         concerning such disposition, the Separation Team described in Section
         2.18 will make the decision resolving such conflict shall be made
         pursuant to Section 2.18.

                                       36
<PAGE>

                  IN WITNESS WHEREOF, the parties hereto have caused this
         Intellectual Property Transfer Agreement to be duly executed as of the
         date first written above.

                              PHARMACIA CORPORATION
                              a Delaware corporation

                              By: /s/ Christopher J. Coughlin
                                  -------------------------------------
                                  Christopher J. Coughlin
                                  Executive Vice President and Chief
                                  Financial Officer

                              MONSANTO COMPANY
                              a Delaware corporation

                              By: /s/ Hendrik A. Verfaillie
                                  -------------------------------------
                                  Hendrik A. Verfaillie
                                  President and Chief Financial Officer

                                       37

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00015-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00015-of-00352.parquet"}]]